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Summary 
Bacterial genome-sequencing projects have revealed that a large number of natural product 
biosynthetic pathways presented in genomes are cryptic. Cloning, engineering and expression 
of a cryptic biosynthetic pathway in a well-characterized heterologous host to discover and 
optimize its product is an effective alternate to traditional approaches.  
We developed RecE/RecT mediated linear-linear homologous recombination (LLHR) for 
direct cloning of ten unknown NRPS/PKS gene clusters from the genomic DNA of 
Photorhabdus luminescens into expression vectors in E. coli. Coupled with robust 
heterologous expression in E. coli, the products of plu3263 and plu1881-plu1877, 
luminmides A-G and luminmycins A-C, were determined, respectively. 
By site-directed modification of the third adenylation domain of NRPS Plu3263, we 
efficiently created mutants using ccdB counterselection recombineering, which led to a 
significant alteration of relative yields of luminmides A and B. 
Partial syringolin biosynthetic pathway (sylCDE) from Pseudomonas syringae was cloned by 
LLHR and expressed in E. coli resulting in the identification of two new syringolins. Intact 
syringolin pathway was reassembled by addition of sylAB and engineering of promoter via 
Red/ET recombineering. The varying production distribution of syringolins showed the 
different efficiencies of native and synthetic promoters in E. coli. 
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Zusammenfassung 
Bakterielle Genom-Sequenzierungsprojekte zeigten, dass zahlreiche im Genom vorhandene 
Sekundärmetabolit Biosynthesewege kryptisch sind. Um die Produkte zu entdecken und 
optimieren, ist Klonierung, Engineering und Expression von diesen Biosynthesewegen in 
einem gut charakterisierten heterologen System eine effektive Alternative zu traditionellen 
Ansätzen. 
Wir entwickelten die von RecE/RecT vermittelten linear-linear homologen Rekombination 
(LLHR) für die direkte Klonierung von zehn unbekannten NRPS/PKS-Genen aus Genom von 
Photorhabdus luminescens in E. coli-Expressionsvektoren. Mittels robuster heterologer 
Expression in E. coli wurden die Produkte von plu3263 und plu1881-plu1877, Luminmide A-
G und Luminmycin A-C, jeweils identifiziert. 
Die ''site-directed'' Modifikation der dritten Adenylierungsdomaine von NRPS Plu3263 
wurde effizient durch ccdB Conter-selektion Rekombination erstellt. Das führte dazu, dass 
sich die relative Ausbeute von Luminmides A und B stark veränderten. 
Der partielle Syringolin Biosyntheseweg (sylCDE) aus Pseudomonas syringae wurde durch 
LLHR kloniert und die Expression in E. coli versursachte die Identifizierung von zwei neuen 
Syringolinen. Der intakte Syringolin Biosynthesesweg wurde durch Zugabe von sylAB und 
Promotor-Engineering via Red/ET-Rekombination wieder zusammengesetzt. Die variierende 
Verteilung der Produktion aller Syringolin-derivate zeigte die unterschiedliche Effizienzen 
zwischen nativen und synthetischen Promotoren in E. coli. 
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A. Introduction 
1 The impact of natural products on drug discovery 
Nature has evolved over a long time to generate a huge number of natural products with 
surprising novelty, diversity and bioactivity.
1-3
 These molecules have played an important 
role across the world in treating and preventing human diseases and agricultural pests for 
thousands of years.
4,5
 Since the middle of last century, natural products have formed a central 
pillar of the modern pharmaceutical industry.
6
 From 1981 to 2010, 1355 new chemical 
entities (small-molecule drugs) were introduced into clinical use, and 64% of them are of 
natural-product origin or inspired derivatives, with the number rising to 68.4% and 74.9% 
when limited to drugs as anti-infective and anticancer molecules, respectively.
7
 The 
discovery and development of antibiotics (e.g., penicillin, tetracycline, erythromycin, 
vancomycin), antiparasitics (e.g., avermectin), antimalarials (e.g., quinine, artemisinin), lipid 
control agents (e.g., lovastatin and analogs), immunosuppressants for organ transplants (e.g., 
cyclosporine, rapamycins) and anticancer drugs (e.g., taxol, doxorubicin, epothilone) based 
on natural products revolutionized medicine, and extended people’s life expectancy (Figure 
A-1).
8
 In addition, natural product-based environment friendly pesticides, such as fungicides 
(e.g., strobilurins, kasugamycin), insecticides and miticides (e.g., avermectin, spinosyns, 
pyrethroids, neonicotinoids), and herbicides (e.g., glufosinate, sulcotrione), reinforced fungal, 
insect, and weed management in agriculture and forest, and improved people’s life quality.5  
Figure A-1. Examples for important natural compounds in clinical and agricultural applications. 
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This fact, allied with the lack of marketed or late phase clinical candidates from 
combinatorial chemistry, increases the confidence that natural products will continue to fulfill 
their role as a major source of new antibiotics or anticancer drugs for the predictable 
future.
9,10
 
Compared to plants and animals, microorganisms are the dominant sources of natural 
products in clinical and agricultural use because they are often renewable, thus opening up 
the possibility to scale-up production.
11
 In addition, the increased understanding of microbial 
secondary metabolite biosynthesis and regulation coupled with advances in molecular 
genetics drive us to focus on the microbial natural products′ discovery and optimization at the 
post-genomic era. 
2 Biosynthetic logics of microbial natural products 
Microbial natural products are chemical compounds isolated from microbes. These 
compounds may derive from microbial primary or rather secondary metabolism. The primary 
metabolites (polysaccharides, proteins, nucleic and fatty acids) are common in all biological 
systems. While secondary metabolites are low molecular (MW<3000), they represent 
chemically and taxonomically extremely diverse compounds and their biosynthesis starts 
from some primary metabolites or from intermediates of the primary metabolism. Microbial 
secondary metabolites are mainly classified as polyketides, peptides, oligosaccharides, 
terpenoids and alkaloids.
12
 But the majority of bacterial secondary metabolites isolated so far 
are polyketides and nonribosomally biosynthesized peptides, or hybrids thereof, which are 
biosynthesized by large molecular assembly lines composed of polyketide synthases (PKSs) 
and nonribosomal peptide synthetases (NRPSs) multienzymes.
13-15
 It should, however, be 
noted that many bacterial natural products are derived from other pathways, such as 
isoprenoid or shikimate pathways.
16-18
 
PKSs are multifunctional and multimodular enzymes; each module contains a set of 
distinct, non-iteratively acting activities responsible for several biosynthetic steps during the 
catalysis of one cycle of the polyketide chain elongation.
19
 The basic domain equipment of a 
typical PKS module includes: the C–C bond-forming ketosynthase (KS) domain; the 
acyltransferase (AT) domain, which introduces malonyl or methylmalonyl units during each 
cycle of chain elongation; and the acyl carrier protein (ACP) domain, also known as a 
thiolation (T) domain where the acyl chain is assembled and elongated. Furthermore, a 
variety of optional domains may be present for modification of the polyketide intermediate, 
including ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER) domains. The last 
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module of the PKS assembly line usually harbors a thioesterase (TE) domain, which in 
charge of the release of the biosynthetic intermediate in linear, cyclic or branched cyclic 
forms (Figure A-2a).
14
  
 
Figure A-2. Biosynthetic logics of bacterial PKS and NRPSs. a) Generalized example of a modular  
PKS consisting of non-iteratively acting domains; acyltransferase (AT), acyl carrier protein (ACP), 
ketosynthase (KS), ketoreductase (KR), dehydratase (DH), enoylreductase (ER), thioesterase(TE); the 
specificity of the AT domain for malonyl-CoA (M-CoA) or methylmalonyl-CoA (MM-CoA) is 
indicated. b) Generalized example of NRPS biosynthesis; adenylation (A), peptidyl carrier protein (T), 
condensation (C), epimerization (E), heterocyclization (HC), oxidation (Ox). The substrates for NRPS 
modules are Val, Ala, Ala, Thr, and Cys, respectively. 
NRPSs are similar to the PKSs; they are also multifunctional enzymes that are organized 
into modules for the incorporation of one amino acid per module.
20
 NRPS elongation 
minimal module consists of an adenylation (A) domain, a condensation (C) domain and a 
peptidyl carrier protein (PCP), for incorporation of one amino acid into the polypeptide 
intermediate. The A domains select and activate the amino acids as substrates and thereby act 
as gatekeepers for specificity of NRPS modules. On the basis of the crystal structure of 
PheA,
21
 a Phe-activating A-domain from gramicidin S synthetase, combined with 
phylogenetic analysis and biochemical studies, 10 active-site residues, designed as 
‘specificity-conferring code’ or ‘non-ribosomal code’, that are responsible for binding the 
amino acid substrates were proposed.
22-24
 This code allows us to predict the substrate 
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specificity of NRPS from their primary protein sequences.
25-27
 Furthermore, by changing as 
few as one of these residues, it has been shown possible to switch the specificity from one 
amino acid to another in vitro and in vivo, even to a non-natural amino acid.
22,28-35
 The C 
domains is similar to KS domains in PKS which is the chain-elongating catalyst via 
formation of peptide bonds. The function of PCP domain is equivalent to the role of ACP in 
PKS assemble lines. Optional tailoring domains include epimerization (E), methyltransferase 
(MT), heterocyclization (HC) and oxidase (Ox) domains (Figure A-2b).
14
 The termination 
modules of NRPS assembly lines usually have a C-A-T-TE organization, and thioesterase 
(TE) domain usually catalyzes the hydrolysis or cyclization for nascent products to form 
linear or cyclic peptides.  
In addition, both PKS and NRPS require a post-translational modification by a 
phosphopantetheinyl transferase (PPTase).
36
 The PPTase catalyses the covalent attachment of 
a 4’-phosphopantetheine moiety, derived from coenzyme A, to the peptidyl (NRPS), or acyl 
(PKS) carrier proteins, which converts the enzyme from the inactive apo- to the active holo-
form. 
3 The impact of bacterial genomics on the natural product research 
Genes encoding these PKSs and NRPSs in bacteria are often clustered in one region of the 
chromosomes, thus the PKS/NRPS-derived biosynthetic pathways are also known as 
biosynthetic gene clusters. These megasynthetases are characterized by having repeat motifs 
in the same functional domains (e.g., KS and AT domains in PKS, C and A domains in NRPS) 
which make them easier to be annotated from the genomic sequences in silico.
37,38
 With the 
progress in the genome sequencing, a large number of bacterial genomes have been 
sequenced. These genomic data have unveiled that the genetic potentials of secondary 
metabolite biosynthesis in the bacteria producing natural products via PKS and NRPS are 
remarkably higher than the amount of known compounds identified from these bacteria 
(Figure A-3).
11,37,39
 For examples, Streptomyces coelicolor and S. avermitilis which were 
known to produce 4 and 3 secondary metabolites at the time of genome sequencing, but 
actually possess 20 and 25 PKS/NRPS clusters for secondary metabolite biosynthesis, 
respectively.
40,41
 Even more unexpectedly, many microorganisms that were not known as 
natural product producers also contain the typical PKS/NRPS clusters for the production of 
hypothetical or unidentified secondary metabolites.
11
 These gene clusters that encode 
biosynthetic pathways whose products have not yet been detected are referred as ‘cryptic’ or 
‘orphan’ biosynthetic pathways.42,43 The following efforts to decode these cryptic gene 
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clusters supported a renaissance in natural product research.
44
 With continuously increasing 
numbers of genome sequences and metagenomics data, it becomes more and more apparent 
that the compounds identified by classical phenotypic screening and bioassay-guided 
fractionation only represented the tip of the iceberg,
39
 because either their hosts cannot be 
cultivated or if they can, the low expression level of pathways in laboratory conditions 
resulting in low amount or nonproduction of natural products that often precludes them from 
being discovered during conventional screening.
45
 Even if a compound is detected, low yield 
and unstable production may restrain subsequent purification, structure elucidation and 
biological activity test. Thus there is a wealth of natural product chemistry that remains to be 
uncovered.   
 
Figure A-3. Biosynthetic potentials of selected fully sequenced prokaryotic natural product producers. 
Identified PKS and/or NRPS biosynthetic gene clusters are shown as black bars, isolated polyketides 
(PKs), nonribosomal peptides (NRPs) and PKS/NRPS hybrid compounds known at the time of the 
genome sequencing are shown as grey bars (The figure adapted from Ref. 11 and 37). 
Strategies to exploit the biosynthetic potential of bacteria like genome mining
46
 and 
microbial metagenomic approaches
47
 have been developed and proven particularly powerful. 
Genome mining is normally based on genome sequence information and aims to correlate 
putative biosynthetic pathways with products. A number of genome mining examples for the 
discovery of ‘hidden’ secondary metabolites, which were not detected by classical screening 
approaches, have been reported in the last decade since the genome sequence projects of 
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several typical natural product producers.
40,41,48,49
 Several recent reviews have systematically 
summarized the current available approaches and strategies of genome mining to discover 
cryptic natural products and their biosynthetic pathways,
43,46,50-54
 such as OSMAC (One 
strain-many compounds),
55
 bioinformatics prediction/subsequent screening for predicted 
properties,
42,56
 gene inactivation studies and metabolite profiling,
57-59
 heterologous gene 
expression and comparative metabolic profiling approach,
60,61
 the genomisotopic approach,
62
 
in vitro reconstitution of biosynthetic pathways,
63
 activation of silent cryptic biosynthetic 
gene clusters by manipulation of regulatory genes and chromatin remodeling,
64-66
 ribosome 
engineering,
67,68
 ‘protein-first’ PrISM (Proteomic Investigation of Secondary Metabolism) 
69,70
 and mass spectrometry-guided natural product peptidogenomics (NPP).
71
  
 
Figure A-3 Selected natural products discovered by genome mining. Pantocin A from Pantoea 
agglomerans and 2-alkyl-4-hydroxymethylfuran-3-carboxylic acid (AHFCA) from Streptomyces 
coelicolor A3(2) by heterologous expression;
60,61
 Koranimine from Bacillus sp. by PrISM;
70
 Nygerone 
A from Aspergillus niger by chemical epigentics methodology;
75
 Aspyridone A from A.nidulans by 
activation of regulatory gene;
66
 Piperidamycin A from Streptomyces sp. 631689 by ribosome 
engineering;
67
 Halstoctacosanolide A from S. halstedii by bioinfromatic analysis;
76,77
 myxoprincomide 
from M. xanthus and myxochromide S1 from Stigmatella aurantiaca by knockout strategy.
57,59 
Most genome mining methods depend on the comprehensive comparative analysis of 
secondary metabolomes between wild type strains and mutants, but the low abundance of the 
corresponding compounds under standard laboratory conditions may have prevented their 
detection by frequently tedious, and lowly sensitive manual comparison of LC-MS data. The 
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Müller group implemented several statistical tools, like principal component analysis (PCA), 
for metabolome mining based on LC-HRMS data.
59,72-74
 Combined targeted gene-inactivation 
studies with a downstream holistic comparison of secondary metabolomes by PCA led to the 
identification of a novel NRPS/PKS natural product, myxoprincomide (Figure A-3), and the 
discovery of two additional new classes of secondary metabolites from myxobacterium 
model strain Myxococcus xanthus.
59
 
In addition, most methods for investigating cryptic gene clusters rely on their functional 
expression in the native hosts. The OSMAC method requires the change of cultivation 
parameters, e.g., medium composition and aeration, to identify conditions that privilege 
expression of secondary metabolites. Targeted gene inactivation and overexpression of 
pathway-specific regulators are also workable only in genetically tractable hosts. The use of 
epigenetic factors to modulate secondary metabolite regulation is often difficult to predict the 
conditions but also, if any, only cause the expression of a particular cryptic gene cluster. 
Furthermore, some natural product producers are difficult to handle and even most of them 
are uncultured. Thus, heterologous expression of cryptic gene clusters in a well-established 
host or a plug-and-play
78
 system using advanced DNA engineering techniques becomes a 
more doable approach, especially for the hard-to-handle native host and uncultured microbes, 
which ultimately leads to discovery of new types of active compounds.
45,79
 The further 
structural diversification of bioactive natural products can be achieved by combinatorial 
biosynthetic engineering in this amenable host. However, the application of heterologous 
expression strategy was stunted by some restrictions, such as difficulties in cloning and 
engineering large gene clusters and lack of suitable heterologous hosts (Section 4).
51
  
4 Heterologous expression of microbial natural products  
The clustered pattern of genes responsible for natural product biosynthesis, regulation and 
resistance in the microbial genomes possibly allows us to clone a gene cluster into a physical 
entity and transfer it into a well-established heterologous host for the production of natural 
products in higher quantities or for the discovery of products. We can also take full advantage 
of the recombinant DNA technologies and tools to generate novel natural product analogs by 
combinatorial biosynthesis methods, circumventing the need to develop a genetic system for 
every microbe producing an interesting compound.
80
 The requirements and challenges 
associated with this strategy are also encountered and mainly include: 1) cloning and 
engineering of biosynthetic gene cluster; 2) selection of suitable heterologous hosts (e.g., 
precursor supply, post-translational protein modification, self-resistance, codon usage).  
A.Introduction                                                         
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4.1 Cloning and engineering of biosynthetic gene clusters 
The cloning and sequencing of bacterial secondary metabolite biosynthetic gene clusters is 
now routine but time and labor consuming, involving the construction and screening of 
cosmid or BAC genomic DNA libraries by random cloning.
10,81
 Generally, relatively small 
biosynthetic pathways (<30kb) can often be cloned within a single cosmid and isolated by 
screening the genomic cosmid libraries of the natural producer strains, as the average insert 
size of a cosmid vector is estimated to be approximately 40 kb. In this case, the biosynthetic 
gene cluster located on one vector can be directly transferred into closely related host, e.g., 
from Streptomyces to Streptomyces, in which the promoter and regulatory elements are 
similar.
82
 However, many natural product biosynthetic pathways are much larger in size than 
the average insert of a cosmid, and some are even larger than fragments commonly found in 
BAC vectors. Thus, the coexpression of several plasmids each harboring parts of biosynthetic 
genes is demanded to achieve heterologous expression of such ample biosynthetic gene 
clusters. Reassembly of a large natural product biosynthetic pathway on one construct before 
transferring into the heterologous host is an alternative to the tedious coexpression procedures. 
By using Red/ET recombineering (section 5.4.1),
83-86
 the complete biosynthetic pathways can 
be stitched together from several cosmids into one construct, followed by the insertion of 
transfer genes (e.g., genes for conjugation), and promoter(s) which is required for 
heterologous expression in unrelated hosts. This is a time-saving method, especially for 
biosynthetic pathways from slow-growing bacteria that can be expressed in a bacterium 
which grows relatively quickly. Several complete biosynthetic pathways, such as 43 kb 
Stigmatella aurantiaca DW4/3-1 myxochromide S gene cluster,
87
 57 kb S. aurantiaca 
DW4/3-1 myxothiazol gene cluster,
88
 the 42 kb Streptomyces sp. Tü6071 phenalinolactone 
gene cluster,
89
 the 32.5 kb S. refuineus anthramycin gene cluster,
90
 the 36.8 kb S. rishiriensis 
DSM40489 coumermycin A1 gene cluster,
91
 the 58 kb Sorangium cellulosum epothilone gene 
cluster,
92
 the 40 kb Cystobacter sp. SBCb004 tubulysin gene cluster,
93
 35 kb S. 
ansochromogenes nikkomycin gene cluster,
94
 have been reassembled by construction and 
screening of cosmid libraries and subsequent Red/ET recombineering mediated stitching and 
modification. A modified version of gene cluster stitching, involving linearization of both 
vectors prior to transformation of recombineering proficient Escherichia coli, was used to 
reconstitute the 38.5 kb Streptomyces nooses subsp. asukaensis asukamycin gene cluster.
95
 
In addition, the large gene cluster can be directly and specifically cloned from sequenced 
genome using transformation-associated recombination (TAR) cloning which uses the native 
recombination potential of Saccharomyces cerevisiae.
96-98
 Brady’s group created pTARa, a 
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BAC-based S. cerevisiae/E. coli/Streptomyces shuttle capture vector.
99
 This vector contains 
elements that allow pathways to be assembled in S. cerevisiae, characterized and maintained 
in E. coli, and conjugatively transferred into a wide range of Streptomyces for heterologous 
expression studies. Using pTARa, they directly cloned the 56 kb colibactin gene cluster 
directly from genomic DNA of Citrobacter koseri.
99
 This method provides a rapid alternative 
to traditionally genomic library for cloning intact natural product biosynthetic gene clusters 
from sequenced microorganisms. To access large, functionally intact, natural product gene 
clusters (e.g., PKSs, NRPSs) from the environment, partial gene clusters need to be 
reconstituted or stitched from metagenomic environmental DNA (eDNA) library clones. The 
same group also used TAR to reconstruct or assemble large gene cluster from several 
overlapping eDNA cosmid clones, resulting in the identification of several new 
compounds.
100
 
An alternative approach is to assemble gene clusters by recently developed synthetic 
biology techniques, such as the Gibson assembly method and DNA assembler,
101-103
 from 
several smaller fragments which can be prepared via standard PCR or direct chemical DNA 
synthesis. But these methods required multiple PCR amplification steps that would introduce 
unexpected mutations, or synthesized DNA that still expensive, and the assembly process 
also causes mutations, insertions, or deletions due to incorrect pairing of fragments.
79
  
The whole or partial natural product biosynthetic gene cluster is usually cloned into an E. 
coli vectors firstly by genomic DNA library or direct cloning method. The subsequent 
manipulation should be determined by strategies of entrance and maintenance in heterologous 
hosts. If the intact gene cluster is already contained in a single plasmid/BAC, the next step is 
to delete non-required gene fragments, to introduce genes for transfer, or to exchange native 
promoters. If the whole gene cluster is found scattered in several plasmids, we can adopt the 
stitching strategy to put all fragments in a single plasmid/BAC, or use multi-plasmid based 
method. The former should be followed by stitching into a BAC or a low copy-plasmid 
through Red/ET recombineering or TAR cloning, while the latter need to change the origin of 
replication and selection marker of plasmids to make them compatible in one cell. 
The challenges of genetic engineering biosynthetic pathways have been generally 
overcome by Red/ET recombineering.
10
 It has streamlined the genetic modification of 
complex biosynthetic pathways by eliminating many of the time-consuming steps in 
traditional digestion-ligation genetic engineering (section 5.4). 
A promoter is a region of DNA that initiates transcription of a particular gene. The native 
promoters present in a specific gene cluster might not be recognized by the heterologous 
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hosts. This problem could mostly be circumvented by chosen of closely related heterologous 
hosts maintaining the native promoters for the genes.
80,82
 However, when the gene cluster 
expressed in a phylogenetically distant host, the native promoter has to be replaced by an 
available promoter in heterologous host to promote the transcription of foreign gene cluster, 
in particular the promoter with inducibility (e.g., the thiostrepton-inducible tipA promoter and 
tetracycline-inducible promoter for streptomycetes,
104-106
 the toluic acid-inducible Pm 
promoter for Pseudomonas strains
87,107,108
 and L-arabinose-inducible PBAD promoter and T7 
promoter for E. coli
109-111
). Inducible expression is desirable particularly in gene clusters 
whose encoded metabolites may be cytotoxic to the hosts. Exchange of the native promoter 
with an inducible promoter not only solves the problem of inefficient transcription in 
heterologous host, but also protects the host from the toxicity of products. If the products are 
not toxic to host or the resistance gene is present in the host, a much stronger or constitutive 
promoter, such as Tn5 promoter,
92
 PaphII promoter,
112
 ErmE promoter,
113
 act promoters
114,115
 
or a synthetic promoter, coupled with optimized ribosomal binding sites, could be used to 
improve the production of secondary metabolites. In addition, the native TTG or GTG start 
codon exchanged for an ATG codon can aid translational efficiency in heterologous host and 
improve production, e.g., the native TTG of tubC was changed to ATG lead to a five-fold 
increase of pretubulysin A production in P. putida.
93
 
 
Figure A-4. Selected natural products that have been successfully expressed in a heterologous host. 
 
A. Introduction 
11 
 
4.2 Selection of suitable heterologous hosts  
It is important to choose a suitable host for heterologous expression of the desired product, 
after the successful reconstitution of biosynthetic gene cluster into a mobile vector system (a 
cosmid or BAC, replicative or integrative, singular or multi-plasmid based) in E. coli. An 
ideal heterologous host should grow fast, be genetically tractable, ensure functional 
expression of the required proteins, provide all necessary precursors and have a low 
background for native secondary metabolites.
80
 Although such an ideal host may not exist for 
all natural products, these criteria can often be met by strains closely related to the native 
producer but with better growth and genetic characteristics. For example, secondary 
metabolite biosynthetic gene clusters from actinomycetes species usually can be successfully 
expressed in some streptomycetes (e.g., S albus, S. lividans, S. coelicolor), all of which are 
suitable for genetic manipulation. However, some phylogenetically distant strains (unrelated 
hosts) provide better results although obstacles, such as codon usage bias, promoter 
recognition, precursor availability and post-translational protein modification, have to be 
overcome by genetic engineering (introduction of an exogenous pathways for supplement of 
precursors and broad substrate specificity PPTases) or precursor feeding. While many 
different bacteria hosts have been used for expression of heterologous genes, E. coli, 
Pseudomonas putida, Myxococcus xanthus, and several Streptomyces species have been 
shown to express large clusters at reasonable initial titers.
116,117
  
E. coli is a model microorganism for genetic and metabolic engineering with a rapid 
growth rate and its use for biological product overproduction (primarily recombinant proteins) 
are also well established. However, E. coli lacks the intracellular machinery (e.g., post-
transcriptional modification, intracellular metabolism, or biosynthetic enzymes) to natively 
produce natural products. Nonetheless, E. coli does have the ability to produce secondary 
metabolites, such as enterobactin (NRP),
118,119
 and the structurally unknown colibactin 
(NRP/PK).
120,121
 The rapid growth rate, easy and cheap scale-up cultivation, various genetic 
manipulation tools, and well-studied genetic system allured people to engineer E. coli for 
producing exogenous natural products. To express 6-deoxyerythronolide B (6dEB), the 
precursor of erythromycin, a phosphopantetheine transferase gene (sfp) from Bacillus subtilis 
was inserted into the E. coli chromosomal prp operon responsible for propionate catabolism 
to delete the prpRBCD genes but leaving the prpE gene under an inducible T7 promoter. 
PrpE converts propionate into propionyl-CoA, one of the precursors needed for 6dEB. The 
propionyl-CoA carboxylase (PCC) from S. coelicolor, was also introduced to convert 
propionyl-CoA to (2S)-methylmalonyl-CoA (MM-CoA), the second precursor required for 
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6dEB formation.
110
 In the heterologous epothilone production, the methylmalonyl-CoA 
decarboxylase gene (ygfG) was replaced by the pcc genes to accumulation of MM-CoA.
109
 
The engineering enables the successful expression of large PKS/NRPS gene clusters, such as 
erythromycin (PKS, feeding of propionate),
122
 yersiniabactin (NRPS/PKS, feeding of 
salicylate),
123
 epothilone (NRPS/PKS, optimized codon usage and feeding of intermediate),
109
 
echinomycin (NRPS),
111
 in E. coli. But heterologous protein folding, foreign codon usage and 
substrate availability must be addressed for further heterologous expression of PKSs and 
NRPSs in E. coli. 
As heterologous hosts for natural products, pseudomonads have several advantages; they 
grow rapidly and are genetically tractable. The high GC genomic content, codon preference 
as well as the possession of PPTases with promiscuous substrate specificity makes them more 
suitable than E. coli for the expression of biosynthetic gene clustes.
124,125
 Müller group has 
successfully expressed several myxobacterial biosynthetic gene clusters (e.g., myxochromide 
S, pretubulysin) in P. putida.
87,93
 However, P. putida cannot provide MM-CoA in a 
detectable level, which precludes the expression of many polyketides. To address this issue, 
methylmalonyl-CoA epimerase, methylmalonyl-CoA mutase, and MeaB (an enzyme 
complex-stabilizing factor) from the myxobacterium S. cellulosum So ce56 were introduced 
into P. putida resulting in a strain producing MM-CoA.
126
 Afterwards, myxothiazol, an MM-
CoA-dependent myxobacterial secondary metabolite, was heterologous produced in this 
engineered strain with a final yield of 600 μg/L.126 An unknown PKS gene from S. cellulosum 
So ce56 was expressed in P. putida yielded flaviolin, a product formerly unknown from 
myxobacteria.
127
 In addition, Pseudomonas strains have also been successfully used to 
confirm the identity of the safracin biosynthetic gene cluster from P. fluorescens A2-2 by 
heterologous expression.
128
 
M. xanthus is the best characterized myxobacterium and possesses more genetic 
engineering tools than all other myxobacteria. It also produces a number of PKS/NRPS 
natural products that showed the presences of PPTases, MM-CoAs, and self-resistance to 
bioactive compounds. Furthermore, M. xanthus exhibits a much shorter doubling time (5 h) 
than S. cellulosum (16h), the anticancer epothilone producer. Thus, Julien and colleages 
introduced the 65.4 kb epothilone gene cluster into M. xanthus that led to production of this 
hybrid PKS/NRPS product.
129
 The Müller group also accomplished the heterologous 
production of myxobacterial secondary metabolites myxochromide S, myxothiazol and 
pretubulysin in M. xanthus.
88,92,93
 In addition to myxobacterial biosynthetic pathways, M. 
xanthus can heterologously express streptomycete-derived oxytetracycline biosynthetic 
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pathway in a high titer 10 mg/L.
130
 The above facts make M. xanthus an attractive potential 
candidate for a ‘universal’ host for facilitating heterologous expression of PKS/NRPS 
biosynthetic pathways from myxobacteria and actinomycetes. 
The Streptomyces or relative actinomycetes have also been harnessed as heterologous 
hosts for the expression of diverse natural products. First, the genus has the ability to produce 
a wide variety of secondary metabolites, which implies that they have sufficient precursors 
and PPTases, and provide resistance mechanisms to sequester themselves from their own 
bioactive compounds. Second, several Streptomyces species, such as S. coelicolor,
40 
Saccharopolyspora erythraea,
48
 and S. avermitilis,
41
 have been sequenced;
 
and the tools for 
genetic manipulation have been established. These characteristics, as well as a nonpathogenic 
nature and established fermentation technology, made Streptomyces an evident option for 
producing natural products, especially for the polyketides.
117
 Secondary metabolites in 
actinomycetes can usually be heterologously expressed in these Streptomyces hosts as 
reviewed by Baltz.
131
  
Moreover, some streptomycetes are also engineered to improve the production of foreign 
products, or to decrease the background metabolite profile. The complete deletion of the gene 
clusters for actinorhodin, undecylprodigiosin, CDA and the cpk cluster
132
 in the heterologous 
host S. coelicolor (M1146) resulted in the 7.5 times increased production of coumermycin A1 
when compared to that in S. coelicolor M512.
133
 The introduction of point mutation into rpoB 
and rpsL in S. coelicolor M1146 dramatically increased the levels of heterologous production 
of chloramphenicol and congocidine and relatively simplified extracellular metabolite 
profiles.
134
 A region of more than 1.4 Mb was deleted stepwise from the 9.02 Mb S. 
avermitilis chromosome to generate a series of defined deletion mutants that did not produce 
any of the major native secondary metabolites found in the original strain.
135
 Exogenous 
streptomycin and cephamycin C biosynthetic pathways were efficiently expressed at levels 
higher than those of the native-producing species. This feature will markedly facilitate the 
discovery of new compounds by heterologous expression of cryptic gene clusters that are 
prevalent within actinomycete genome sequences. 
Considering the growth rate, precursor supply, and self-resistance, the safe selection of 
heterologous host was proposed. Generally, the actinomycete-derived gene clusters are firstly 
considered to the engineered streptomycetes, like S. coelicolor M1146 or M1152, engineered 
S. avermitilis, and then M. xanthus. M. xanthus is also the optimal choice for the expression 
of myxobacterial gene clusters, especially for the polyketide gene clusters. The NRPS gene 
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clusters can be attempted to express in P. putida, and E. coli, but promoter exchange is 
ordinarily essential for successful expression in a distantly related host (Section 4.1).  
4.3 others 
The methods for transfer of biosynthetic gene clusters into heterologous hosts are 
dependent on the choice of hosts (Section 4.2). E. coli is the model genetic engineering 
microorganism and electroporation is the most frequently-used and efficient method to 
transfer of large DNA into most E. coli strain now. Large gene clusters can maintain in E. 
coli by replicative plasmids,
110,111,123
 only few examples by integration of gene clusters into 
the chromosome.
136
 The routine method to introduce foreign DNA into P. putida, and 
streptomycetes is conjugation. The large DNA fragments enter M. xanthus always by 
electroporation. Because no stable plasmid replicon is available for this strain, all of the 
heterologous gene clusters should be integrated into the chromosome. After access into cells, 
the stable maintenance of the foreign biosynthetic gene cluster in a heterologous host is the 
groundwork for successful heterologous expression. The plasmid-based system and 
chromosomal integration are the two prevalent patterns, which have been well-established.
10
 
Biosynthetic gene clusters can be expressed from self-replicating plasmids; either from a 
single plasmid or from multiple plasmids individually expressing modules in cis. Plasmid-
based expression has the benefit of increasing the number of copies of the biosynthetic gene 
cluster which can provide an enhanced titer of compound, but unstability is the main 
drawback of this strategy. The chromosomal integration is more stable and it includes 
homologous recombination by endogenous recombinases in the heterologous host, 
transposition for random integration
92
 and Phage derived integration which mediated by a 
large serine recombinase that catalyzes unidirectional recombination between the 
bacteriophage attP and chromosomal attB sites.
137
  
Once the biosynthetic gene cluster for the desired compound is cloned, transferred and 
stably maintained within a chosen heterologous host, the selection of suitable fermentation 
conditions serves as the last variable to activate or improve metabolite production. Based on 
the many successful examples reported, in most cases the original fermentation conditions 
used with the native producer of the desired compounds can also be applied to the 
experiments within the heterologous host.
80
 The conditions are usually optimized for good 
production of the respective natural product and, at least for host related to the native 
producer; these conditions should provide all the nutrients needed to ensure sufficient growth 
of the respective recombinant strain. For the unrelated host, the condition is difficult to 
predict, but generally, the low temperature incubation and coexpression of chaperones are 
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beneficial for large protein expression which can facilitate the production of desired products, 
especially for the expression of large PKS and NRPS in E. coli. 
110,122
 
Among these, the biggest challenge is the cloning of big size biosynthetic gene clusters, 
though advanced recombinant DNA techniques (i.e., Red/ET recombineering, TAR cloning) 
slightly simplified the procedure for reconstruction of large gene cluster, and promoted the 
genetic engineering of gene clusters. Besides, the efforts to improve the production of 
heterologous products are must be strengthened. 
5 Molecular engineering of microbial natural product pathways 
The genome sequences of natural product producers set the stage for genetic engineering 
of microbial natural product biosynthetic pathways to characterize gene function, generate 
novel derivatives, or improve production yields.  
5.1 General strategies for engineering of natural product pathways 
The biosynthesis of PKs and NRPs that condenses monomeric building blocks into a 
natural product scaffold, uses a process which can be divided into three stages: provision of 
precursors (acyl-CoAs for PKS, amino/aryl acids for NRPS) to feed into the assembly lines; 
PKS/NRPS catalyzes chain initiation, elongation, and termination during assembly; post-
assembly-line tailoring of nascent released product to form mature (bioactive) natural 
products.
138
 Based on the biosynthetic pathway, the modifications to yield new ‘unnatural’ 
natural products should include three levels: Precursor-directed biosynthesis/mutagenesis 
which aims to incorporate modified starter/extender units or biosynthetic intermediates into 
the assembly process by feeding experiments, engineering of the PKS/NRPS assembly line, 
and modification of post-assembly line enzymes (Figure A-5).  
Precursor-directed biosynthesis (PDB) and mutasynthesis utilize nature’s machinery to 
produce complex natural product analogs, which take advantage of the natural flexibility of 
biosynthetic pathways toward the acceptance of unnatural precursor analogs.
139
 The 
alternative biosynthetic building blocks are designed, synthesized and fed to the wild type 
(PDB) or engineered (mutasynthesis) microorganisms to generate the natural products of 
interest.
140,141
 Due to competition with endogenous precursors, the yields of new molecules 
by PDB are usually low. This problem is circumvented in mutasynthesis approaches where 
the native pathway is blocked at specific positions by genetic manipulations (mutagenesis) 
resulting in an abolishment of product formation. The biosynthesis can then be restored by 
feeding appropriate unnatural precursors to the mutant strains to trigger a ‘jump-start’ of the 
assembly process. However, incorporation of the altered precursors requires a broad substrate 
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tolerance of all catalytic activities downstream from the blocked step and, in practice, only a 
subset of analogs will be accepted.
141
  
The modification of the assembly line is generally based on the manipulation, such as 
deletion, insertion, exchange, fusion, and site-directed mutagenesis, of catalytic domains, 
complete modules to cause the alteration of the ‘gatekeeper’ domains, A domains for NRPS 
and AT domains for PKS. By rational manipulation of domains/modules, or site-directed 
mutagenesis, it has been possible to alter the selection of building blocks by domain/modular 
exchange,
142-148
 to increase or decrease chain length by module insertion,
149
 fusion
150
 or 
deletion,
151,152
 to modify the β-keto reduction for PKS by inactivation of active sites or 
domain exchange,
153-156
 or to inactivate tailoring domains in NRPS by point mutations.
157
 The 
recombination of whole modules or domain is a rather drastic intervention in PKS/NRPS 
biosynthesis that usually results in reduced catalytic efficiency and product yields. 
Manipulating the A domain’s specificity through point mutations of substrate-coordinating 
amino acid residues according to the ‘non-ribosomal code’ represent a more conservative 
strategy for NRPS engineering.
158,159
 
 
Figure A-5. Strategies for molecular engineering based on the biosynthetic stages of PKS and NRPS. 
The post-assembly-line tailoring enzymes include glycosyltransferases, methyltransferases, 
halogenases, prenyltransferases, carbamoyltransferases, and oxygenases, which can mature 
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the bioactive natural products. It is possible to generate novel ‘unnatural’ natural products by 
alteration, deletion or insertion of those post-assembly-line tailoring enzymes.  
5.2 Molecular engineering in native producers  
There are two basic ways for engineering of bacterial natural product biosynthetic 
pathways, one is the genetic manipulation in the chromosome of native producers, the second 
being transfer of entire biosynthetic gene cluster into a more amenable heterolgous host 
followed by modification and engineering.
37
 The former way usually requires double 
crossover to introduce, or delete genes, to the best, in a markerless pattern. However, some 
natural product producers, like some myxobacteria and streptomycetes, are growing slowly 
and they are refractory to accept exogenous DNA for elaborate genetic manipulation.  
 
Figure A-6. Examples of molecular engineering of natural product biosynthetic pathaways for 
generating new derivatives. a) Disruptants in salL, a gene encoding the unusual chlorinase can be 
complemented with 5’- FDA in order to generate fluorosalinosporamide. b) Module exchange was 
applied to produce daptomycin derivatives with Trp13 and Ile13. c) Targeted disruption of an 
oxygenase (MbcM), resulting in production of a non-quinone macbecin derivative. 
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In the naive producer, mutasynthesis is the more convenient method to generate new 
derivatives. Eustáquio and Moore disrupted salL, a gene encoding the unusual chlorinase for 
the biosynthetic chlorination of S-adenosylmethionine (SAM), in salinosporamide producing 
strain Salinispora tropica, thereby blocking the halogenation. Complementation of 5′-fluoro-
5′-deoxyadeninoside (5′-FDA) yielded the fluoro derivative fluorosalinosporamide (Figure A-
6a).
160
 Disruptants in rhiA, a gene encoding the heterocyclization in the loading module in the 
rhizoxin biosynthetic pathway coupled with feeding of N-acetylcysteamine derivative led to 
formation of thiarhizoxin in Burkholderia rhizoxinica.
161
 This PDB/mutagenesis method have 
been widely applied in generation of new derivatives for many natural products, such as 
balhimycin,
162,163
 rapamycin,
164
 pacidamycin,
165
 CDA (calcium-dependent antibiotic),
166,167
 
myxalamid,
168
 geldanamycin,
169-172
 erythromycin,
173
 ansamitocin,
174-178
 cryptophycin,
179,180
 
aureothin,
181
 cinnabaramide,
182
 elansolid.
183
  
The modification of PKS and NRPS backbones in the native producer are usually 
performed by gene complementation strategy. Firstly the targeted subunit was cleanly deleted 
by double crossover, and then complemented with a replicative or integrative plasmid 
containing the engineered fragment. An elegant study on the genetic manipulation of the PKS 
assembly line was performed by Kosan Biosciences, Inc.
142
 Genetic engineering of the 
geldanamycin gene cluster (GdmPKS) in native producer S. hygroscopicus resulted in new 
geldanamycin derivatives that selectively lack methyl or methoxy groups in the ansa chain by 
replacement of AT domains in six different GdmPKS modules that commonly accept MM-
CoA or methoxymalonyl-CoA with malonyl AT domains from the rapamycin PKS. Four of 
these manipulations led to the production of 2-desmethyl, 6-desmethoxy-, 8-desmethyl-, and 
14-desmethylgeldanamycin derivatives, the γ,δ-saturated, and the hybridization products. 
Another successful example is the combinatorial biosynthesis of novel antibiotics related to 
daptomycin and A54154. The scientists in Cubist Pharmaceutical used module exchange 
(Figure A-6b), NRPS subunit exchanges, inactivation of the tailoring enzymes, and natural 
variations of the lipid tail based on the daptomycin gene clusters to generate a library of novel 
lipopeptides, some of which show improved properties.
145-147,184-186
 They employed Red/ET 
recombineering to exchange new domains or modules at specific interdomain linker sites 
(Section 5.4.2). Direct double crossover in the native producer was also workable. Marahiel 
group made many efforts in the combinatorial biosynthesis base on this strategy by 
domains/modules exchanges, in-frame module deletion, module fusion, and site-directed 
mutagenesis in the surfactin biosynthetic gene cluster in Bacillus subtilis.
31,144,148,151,187
 It was 
shown possible to switch the specificity of A domain in NRPS from one amino acid to 
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another to change the polypeptide backbone. A second specificity change in module 5 from 
Asp to Asn yielded the expected surfactin derivative in vivo.
31
 The saturation mutagenesis of 
nonribosomal codes on NRPS AdmK allowed generating new andrimid derivatives in 
original producer Pantoea agglomerans.
32
 The deletion or insertion of whole module, or 
domain fusion also was utilized to change the size of NRPS backbones. The directly 
manipulation of biosynthetic gene cluster in the native chromosome is usually difficult and 
tedious, thus ectopic trans-complementation system is an efficient alternative to accomplish 
this goal. 
The inactivation of post-modifying genes can be achieved by simple single crossover to 
produce reduced derivatives, meanwhile to identify the function of inactive genes. For 
example, targeted disruption of an oxagenase involved in post-PKS quinone formation during 
the biosynthesis of an Hsp90 inhibitor macbecin led to the production of a non-quinone 
analog which has an enhanced binding affinity and significantly reduced toxicity compared 
with the parent molecule (Figure A-6c).
188
  
5.3 Molecular engineering in heterologous hosts 
As the mutagenesis of secondary metabolite pathways in the chromosome of natual 
producers is often very difficult except for some relatively genetically tractable strains 
(section 5.2), the robust heterolgous expression of biosynthetic gene cluster in an amenable 
host provides an important basis for the molecular engineering, because the engineering of 
gene cluster in E. coli is usually well-established. The successful expression of echinomycin 
gene cluster in E. coli enabled to produce an unnatural (synthetic) quinomycin antibiotic 
TANDEM by deletion of the gene ecm18 encoding thioacetal formation enzyme and 
inactivation of both MT domains by point mutations in the ecm7 NRPS.
111,157
 The same 
group also substituted an echinomycin biosynthetic gene ecm7, with a gene swb17, encoding 
a bimoduler NRPS that contains the A domain capable of accepting (+)-(1S,2S)-
norcoronamic acid ((+)-NCA) as extender unit, from SW-163 biosynthetic gene cluster. This 
rational engineering of plasmid-based echinomycin biosynthetic pathway and feeding of a 
chemically synthesized precursor (+)-NCA caused L-Val in echinomycin was replaced with 
(+)-NCA and further production of a novel bioactive compound ecolimycin C in E. coli.
189
 
This showed that E. coli-based plasmid-borne heterologous natural product biosynthetic 
expression can not only facilitate the reconstruction of various biosynthetic gene clusters but 
also afford an applicable platform for rational redesigning of biosynthetic pathways through 
modular reassembling of the genes from another biosynthetic cluster. In addition, the loading 
module of DEBS1 was replaced with the loading module from the rifamycin PKS and this 
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change led to the production of an analog of erythromycin D with a designed benzyl unit in E. 
coli at a titer of 0.5 mg/L. Similarly, the second module of DEBS3 was altered to accept a 
malonyl-CoA extender unit, which resulted in the lack of a methyl group at the C2 position of 
erythromycins A-D at titers between 0.05 and 0.2 mg/L.
122
 The reengineering of 
megaenzymes is usually performed in E. coli, but expression is not always functional in E. 
coli, and the limiting factor is the lower or no product titers.  
The large gene cluster can also be modified in E. coli using Red/ET recombineering and 
then transferred into the heterologous host for robust gene expression. Heterologous 
expression of the reconstituted gene cluster in S. coelicolor M512 resulted in the production 
of coumermycin A1. Inactivation of the MT gene couO by Red/ET recombineering and 
heterologous expression of the modified cluster led to an accumulation of a C-8-unsubstituted 
coumermycin A1 derivative. Subsequent expression of the halogenase gene clo-hal from the 
clorobiocin gene cluster in the heterologous producer strain resulted in the formation of two 
new hybrid antibiotics.
91
 The same group also produced 8-halogenated and 8-unsubstituted 
novobiocin derivatives in genetically engineered S. coelicolor strains.
190
 Similarly, deletion 
of a glycosyltransferase–encoding gene plaA6 from the phenalinolactone expression 
construct by Red/ET recombineering gave rise to a novel, unglycosylated phenalinolactone 
derivative in the heterologous host S. coelicolor M512.
89
 Inactivation of p-aminobenzoate 
synthase gene aurG involved in the formation of the natural aureothin starter unit (p-
nitrobenzoyl-CoA) via Red/ET recombineering, and expression of the modified pathway in S. 
lividans, resulted in mutants lacking aureothin production. Addition to the non-natural 
substrate p-cyano benzoate to this mutant resulted in the production of a new nitrile analog 
from aureothin, aureonitrile, which shows significantly enhanced biological activity.
181
 This 
can be considered as the mutasynthesis in the heterologous host, analogously, the precursor-
directed biosynthesis of epothilone was also achieved in a heterologous host E. coli.
191  
The biosynthetic gene cluster can also be reconstructed from PCR-amplified multiple 
DNA fragments by DNA assembler (Section 4.1) via in vivo homologous recombination in S. 
cerevisiae. This method is flexible for genetic manipulations, such as site-directed 
mutagenesis, scar-less gene deletion and insertion, of the target pathway. The Zhao group 
created point mutations onto the core motif of DH domain in AurB in the aureothin 
biosynthetic pathway using DNA assembler and expressed the resulting mutants in 
heterologous host S lividans led to expected production of a new hydroxyl aureothin together 
with the original compound.
103
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A couple of new derivatives have been successfully generated by the combinatorial 
biosynthesis in the relatively amenable hosts, such as E. coli, streptomycetes, but the difficult 
in cloning of large gene cluster and low titers of heterologous expression (lack of appropriate 
heterologous host) restricted the application of this strategy. In addition, design of 
modification of biosynthetic pathways needs the detailed understanding of protein-protein 
interaction in the gene cluster.
82
 Amongst them, the cloning of large gene cluster into E .coli 
is the primary issues and the prerequisite for prosperous heterologous expression and 
molecular engineering to exploit the natural products. Thus more convenient and advanced 
DNA cloning techniques are required to efficiently clone and manipulate large DNA 
fragments.  
5.4 Red/ET recombineering facilitates molecular engineering 
5.4.1 Red/ET recombineering 
Red/ET recombineering, also known as ‘ET cloning’,83 ‘ET recombination’,84,85 ‘λ Red 
recombination’86,192 or ‘recombineering’,193,194 is an in vivo homologous recombination-based 
genetic engineering method employed primarily in E. coli by using short homology arms, 
which is based on the expression of either redα/redβ from the Red operon of λ phage86 or the 
analogous recE/recT from Rac prophage
83
 that are located in the E. coli K12 chromosome. In 
the interests of clarity, Stewart referred to the homologous recombination in E. coli, mediated 
by either RecE/RecT or Redα/Redβ, as Red/ET recombination.195 In this thesis, we prefer to 
use Red/ET recombineering for all the techniques involving RecE/RecT or Redα/Redβ.  
The Rac operon and the λ Red phage are functionally equivalent.196 RecE and Redα are 5′ 
to 3′ exonucleases, RecT and Redβ are single strand DNA-binding proteins (SSAP) with 
annealing and strand exchange activity, Redγ is a inhibitor of nuclease RedBCD and prevent 
the degradation of linear DNA fragment.
197
 The Red/ET recombineering is started with the 
RecE or Redα protein binds to linear DNA and degrades the linear DNA in a 5′ to 3′ direction, 
thereby exposing a 3′ single strand DNA (ssDNA) overhang. Then, RecT or Redβ binds to 
the ssDNA, forming a recombinogenic proteonucleic filament which is used in recombination, 
either by single strand annealing or by strand invasion (Figure A-7).
198-200
 In the annealing 
model, the protein-ssDNA filament anneals to a complementary single-stranded region that 
has arisen from either a similarly prepared double strand break (DSB) or from a DSB 
produced by DNA replication. In the strand invasion, the protein-ssDNA filament establishes 
a D-loop in an unbroken DNA region.
200
 The resulting recombinants can be acquired after the 
repair and replication.  
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In comparison to Redα, RecE is a much larger protein. The C terminus starting at residue 
588 (RecE588) of which only constitute the exonuclease domain, together with RecT, was 
used for recombineering and they are better than the full length RecE/RecT.
83
 But 
RecE588/RecT pair was less efficient than the Redα/Redβ pair for homologous 
recombination, thus the Red system was extensively applied for precise insertion, deletion 
and insertion of sequence of interest.
85,92,192,201-203
 This kind of Red/ET recombineering 
approaches relied on homologous recombination occurring between linear (generally PCR 
products) and replicating circular DNA molecules, termed it LCHR (linear plus circular 
homologous recombination). It is proficient with homology arms as short as 40-50bp and 
permits the use of polymerase chain reaction (PCR)-amplified fragments generated from 
oligonucleotides synthesized to introduce the short homology arms.
192,204
 As Red/ET 
recombineering is based on homologous recombination, it allows precise modification 
bacterial chromosomes or any episomal DNA in E. coli and is independent on the location of 
restriction sites.  
 
Figure A-7. Two classical models for Red/ET recombineering using double-stranded DNA as a donor. 
(The figure adapted from Ref.196) 
Besides linear double-stranded DNA (usually in the pattern of PCR products), synthetic 
oligonucleotides or single-strand DNA (ssDNA) can also be substrate of recombineering, 
named as ‘single stranded oligo repairing (ssOR)’, or oligonucleotide-mediated 
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recombineering, which can be used to create single base changes, inserts and substitute short 
DNA sequences, and generate deletions.
195,205
 The repair by oligos that hybridized with the 
lagging strand template (lagging) is consistently higher than repair by oligos that hybridize 
with the leading strand template (leading) (Figure A-8).
195,205
 The phage annealing proteins, 
RecT or Redβ, mediated ssOR-directed mutagenesis allow rapidly and efficient introducing 
point mutations in BACs or chromosomes by a counterselection-based recombineering 
method.
195,206,207
 A major problem in counterselection is intramolecular recombination; hence 
some improvements have been made to reduce these unwanted events by expressing Redβ 
alone at crucial step, and enhance the efficiency by using phosphothioated 
oligonucleotides.
206
 
 
Figure A-8. Current model for oligonucleotide-mediated recombineering. RecT or Redβ promotes 
annealing of an oligonucleotide to ssDNA of the lagging strand template of a replication fork. 
Following elongation by DNA polymerase I and ligation to neighboring Okazaki fragments, the 
oligonucleotide is incorporated into the DNA. (The figure adapted from Ref.208) 
Owing to its short homology requirements and high efficiency, Red/ET recombineering 
can be extensively utilized in DNA engineering.
208
 It can be used to accurately insert 
selectable or nonselectable markers in plasmids, bacterial chromosomal DNA or BACs 
without size limits, to generate gene-targeting constructs for making reporter-tagged and 
conditional alleles in embryonic stem cells.
209
 It can also be used to generate subtle 
alterations in BACs or bacterial chromosomal DNA by counterselection recombineering 
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without site-specific recombination system.
194
 Moreover, Red/ET recombineering can be 
applied to clone and subclone certain DNA regions of interest from a DNA source (e.g., 
plasmid, BAC, genomic DNA), into a plasmid. 
84
 
5.4.2 Red/ET recombineering mediated engineering of biosynthetic gene clusters 
 
Figure A-9 Diagram for stitching of the epothilone gene cluster. pSuperCos-epo35 was retrofitted 
with the p15A origin and the chloramphenicol resistance gene to remove the pSuperCos backbone and 
introduce the short homology arm ‘a’ to create p15A-epo35. pSuperCos-epo14 was digested with ScaI 
and the epoA-D genes were recombined into p15A-epo35 by triple recombination using a bridging 
zeocin (zeo) resistance gene with a 5′ end homology arm to p15A-cm-epo35 (‘a’) and a 3′ end 
homology arm  to a region in front of epoA in pSuperCos-epo14 (‘b’). (The figure adapted from 
Ref.92) 
Using Red/ET recombineering, the large gene cluster spanning in several cosmids can be 
stitched into a single plasmid or BAC, which is simple and convenient for the further 
modification and delivery. Then genetic elements required for the transfer and integration 
into the chromosome were introduced, if necessary, the original promoter was exchanged 
with a promoter which is available in the unrelated host. Figure A-9 shows the stitching of 
the 61 kb epothilone gene cluster from two cosmids by triple recombination.
92
 The stitching 
was based on two rounds of recombineering and the generation of two intermediates (zeo 
PCR product and linear epoA-D fragment) (Figure A-9). The subsequent insertions of genetic 
elements for gene transfer, stable integration, and regulated expression can be completed by 
further Red/ET recombineering. The most important advantage of this method is that the 
pSuperCos-epo35
subclone
+
triple recombination
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whole secondary metabolite pathway is located on one construct, which can be transferred 
into the heterologous host strain once. As recombineering is based on homologous 
recombination, one might have expected difficulties using the described method in the 
assembly of repetitive sequences. Nevertheless, in related report employing gene clusters up 
to 80 kb in size demonstrated that highly repetitive sequences can be recombined 
efficiently.
87
 
 
Figure A-10. Red/ET recombineering mediated module exchange for construction of hybrid dptBC in 
daptomycin biosynthetic pathway. ha means 45-bp homology arm. (The figure adapted from Ref.145) 
The other important application of Red/ET recombineering is the engineering of large 
gene clusters. The seamless and precise recombination of a sequence of interest flanked by 
homologous ‘arms’ to any targeted location on a replicating DNA molecule is extremely 
important for engineering of PKS/NRPS assembly lines, because in some case even the 
alteration of one base pair would lead to complete loss of product. The modular/domain 
exchange, deletion, or insertion, and precise point mutations can be accomplished by Red/ET 
recombineering mediated strategy. For example, in the module exchange of daptomycin 
biosynthetic gene cluster (Figure A-10),
145
 the targeted module was initially replaced with a 
durg resistance gene flanked with rare restriction sites AvrII or PmeI by Red/ET 
recombineering (gene disruption). The cassette was then excised, and the linearized plasmid 
was used for ligation. In the meanwhile, the DNA fragment coding for another CAT domains 
was cloned by the ‘gap-repair cloning’ method using Red/ET recombineering, the suitable 
C AOrn T C AAsp T C AAla T C AAsp T C AGly T C ASer TE E
AvrII PmeI
ha ha
Drug resistance gene
AvrII PmeI
Deletion cassette
C AOrn T C AAsp T C ASer T C AAsp T C AGly T C ASer TE E
Gene disruption
NheIHpaI
ha ha
NheI HpaI
NheI HpaI
Gap repair cloning
Restriction digest
Ligation
Gene replacement C-ASer-T
dptBC
Insert excision
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restriction sites, HpaI and NheI, were also added in both termini. The gap repair cloned 
fragment was cut off and used in ligation with the linearized targeted plasmid by the 
compatible restriction sites for gene replacement. This strategy leads to the remains of 
splicing sites in the T-C linker, the T-E linker or the E-C linker and further incorporation of 
amino acid residues in these regions. But these subtle alterations seemingly have no big 
effects on the final expression.
145
 Using this method for module/domain substitution 
combined with deletion of tailoring genes, 120 novel lipopeptides were generated based on 
daptomycin and A54154, and over 40 novel lipopeptide antibiotics were produced in 
sufficient quantities for facile isolation, confirmation of structure, and analysis of 
antibacterial activities.
186
 Importantly, some of the compounds displayed the desired 
properties of antibacterial activities similar to those of daptomycin, minimal or no inhibition 
by surfactant, and low mammalian toxicity.  
For the deletion of post-assembly-line tailoring enzymes, one round of Red/ET 
recombination is harnessed to replace a target gene with a antibiotic resistance gene flanked 
by site-specific recombination sites (i.e., LoxP, FRT)
89,210
 or rare restriction sites,
91
 and 
subsequent site-specific recombination (Cre-LoxP or Flp-FRT) (Figure A-11) or religation to 
remove selection marker for in-frame deletion, but this resulted in a short ‘scar’ sequence 
remaining.  
 
Figure A-11. Deletion of the glycosyltransferase encoding gene plaA6 by using a kanamycin-
resistance cassette that was flanked by FRT recognition sites. Red/ET recombineering was used to 
replace plaA6 with the kanamycin-resistance cassette. Incubation with FLP recombinase at 37 °C led 
to a markerless deletion of plaA6 in the pla cluster. (The figure adapted from Ref. 89) 
The emergence of Red/ET recombineering extremely promotes the engineering of large 
natural product biosynthetic gene cluster in E. coli. Coupled to efficient heterologous 
expression, it will facilitate the natural product bioprospecting at this post-genomic era. 
H1 FRT
H2
FRT
plaA5 plaA7plaA6
km resistance
FRT FRT
34 bp-FRT
FLP recombinase
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6 Outline of my dissertation 
The aim of this thesis was to develop technology to improve discovery and modification 
of bacterial natural products based on the increasing numbers of sequenced bacterial genomes. 
Together with the progress of DNA engineering techniques, such as Red/ET recombineering, 
the large secondary metabolite biosynthetic gene clusters can now be rapidly cloned and 
engineered. When these steps are followed by robust expression in a suitable heterologous 
system, the products encoded by cryptic biosynthetic gene clusters can be identified, and 
even optimized by combinatorial biosynthetic engineering. The present thesis involves rapid 
cloning, genetic engineering, and heterologous expression of several bacterial secondary 
biosynthetic gene clusters via Red/ET recombineering. In particular, luminmide and 
luminmycin biosynthetic pathways from an entomopathogenic bacterium Photorhabdus 
luminescens subspecies laumondii strain TT01 (DSM15139), and syringolin biosynthetic 
pathway from Pseudomonas syringae pv. syringae (DSM1242) were investigated. In addition, 
an improved technique for modification of biosynthetic pathway by ccdB counterselection 
recombineering was introduced.  
Laborious and time-consuming DNA library construction and screening are required for 
recovering large genomic sequences of interest, e.g. secondary metabolite biosynthetic 
pathways. In Section B Chapter 1, we describe direct DNA cloning based for the first time 
to discover that the full-length Rac prophage protein RecE (866 amino acids) and its partner 
RecT mediated highly efficient homologous recombination between two linear DNA 
substrates, which is mechanistically distinct from conventional replication-dependent 
recombineering meditated by Redαβ from lambda phage or truncated version of RecET. This 
finding had immediate implication for cloning of linear DNA constructs from bacterial 
artificial chromosomes, cDNA and genomic DNA into linear vectors in E. coli. The 
capability of direct cloning was demonstrated by successfully cloning ten cryptic natural 
product biosynthetic gene clusters (each 10-52 kb in length) from digested genomic DNA of 
P. luminescens into expression vectors. When these cloned PKS/NRPS gene clusters were 
transformed into E. coli GB05-MtaA and Nissle 1917, two of them, plu3263 and plu1881-
plu1877, produced new groups of compounds at an immediate detectable level (>0.1mg/L). 
They were designated as luminmides and luminmycins, respectively.  
The luminmycin biosynthetic pathway shows high similarity with that of glidobactin in 
Burkholderia DSM2029 except for the absence of a homologue of the biosynthetic gene glbH. 
This gene encodes a dioxygenase which has been proposed to add the -OH group to the lysine 
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in the12-membered ring. Addition of glbH into the luminmycin gene cluster plu1881-plu1877 
leads to partial conversion from luminmycin A to glidobactin A which shows higher cytoxic 
and antifungal activity. Luminmycins A-C were isolated from the heterologous host and their 
structures were elucidated using 2D NMR and HRESIMS in Section B Chapter 2 (Figure A-
12). Luminmycin A is a dehydroxy derivative of the previously reported glidobactin A, while 
luminmycins B and C most likely represent its acyclic biosynthetic intermediates. 
Luminmycin A showed cytotoxicity against human colon carcinoma HCT-116 cell line with 
an IC50 value of 91.8nM while acyclic luminmycin B was inactive at concentrations as high 
as 100 µg/mL.  
Plu3263 is encoded by a 15.6 kb NRPS gene and it contains five NRPS modules and 
produces a group of cyclic peptides, luminmides A-G, when it expressed in E. coli GB05-
MtaA. These luminmides were identified by HRMS, direct and inverse feeding experiments 
and 2D-NMR in Section B Chapter 1 and Chapter 4 (Figure A-12).  The third module 
(C/E-A3-T) can activate and incorporate five different amino acids, Phe, Leu, Try, Met, and 
Ala, into the final cyclic pentapeptides, which suggest the C/E and A domain in this module 
exhibits broad substrate specificity and the exnyme system also shows downstream toleration 
for altered substrates in subsequent steps. Section B Chapter 3 describes the efficient point 
mutation of a multi-copy plasmid and BACs by using ccdB counterselection recombineering. 
In Section B chapter 4, we employed ccdB counterselection recombineering to create single 
or double mutations at the ‘specificity-conferring codes’ of A domain in a complex NRPS 
gene plu3263 efficiently. Followed by subsequent robust expression of mutants in E. coli, the 
minor product luminmide B was changed to be prominent in several mutants without 
significant reduction of product yields, even higher (A301G) than the wild type, while the 
dominating luminmide A in the wild type Plu3263 was decreased to different extent in all the 
mutants. This fact showed the feasibility of alteration of the specificity of A3 domain by site-
directed mutagenesis. 
The syringolin biosynthetic gene cluster (sylCDE, 19 kb) from a digested genomic DNA 
mixture of P. syringae was directly cloned into a plasmid in which sylCDE is under the 
control of an inducible promoter by one step linear plus linear homologous recombination 
(LLHR) in E. coli in Section B chapter 5. After expression in E. coli GB05-MtaA, two new 
syringolin derivatives (sryingolin G and H) were discovered (Figure A-12). The complete 
syringolin gene cluster was assembled by addition of sylAB and exchange of a synthetic 
bidirectional promoter against the native promoter to drive sylB and sylC expression by using 
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Red/ET recombineering. The varied production distribution of syringolin derivatives showed 
the different efficiencies of native and synthetic promoters in E. coli. 
The direct cloning and engineering of natural product biosynthetic pathways by Red/ET 
recombineering coupled with suitable heterologous expression hosts represents an effective 
approach to investigate or optimize known and unknown biosynthetic pathways discovered 
by bacterial genome sequencing projects, especially from slow growing bacteria and such for 
which genetics tools are only poorly established. 
 
Figure A-12. Structures of newly identified natural products in this thesis. 
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ABSTRACT 
Recombineering, which is the use of homologous recombination for DNA engineering in 
Escherichia coli, usually employs antibiotic selection to identify the intended recombinant. 
When combined in a second step with counterselection, seamless products can be obtained. 
Most counterselection options employ drug selection. Here, we report the advantages of a 
non-drug strategy using ccdB as the counterselectable agent. Expression of CcdB is toxic to E. 
coli in the absence of the CcdA antidote so the counterselection step is initiated by the 
removal of CcdA expression. Because counterselection strategies necessarily differ according 
to the copy number of the target, we describe two variations. For multi-copy targets, we 
employ two E. coli hosts so that counterselection is exerted by the transformation step that is 
needed to separate the recombined and unrecombined plasmids. For single copy targets, we 
put the ccdA gene onto the temperature-sensitive, pSC101 Red expression plasmid so that 
counterselection is exerted by the standard temperature shift to remove the expression 
plasmid. Hence this drug-free counterselection method is less work than existing methods 
and will be useful for genetic engineering not only BACs and plasmids, but also the E. coli 
chromosome.  
INTRODUCTION 
DNA engineering methods are central to molecular biology. However, the original, 
revolutionary, ‘cut and paste’ methods based on restriction enzymes and DNA ligations are 
limited to engineering exercises for small DNA molecules. Recombineering using phage 
protein-mediated homologous recombination in E. coli (1-10) was developed to engineer 
cloned DNA molecules of all sizes. Recombination occurs through homology regions, which 
are stretches of identical DNA sequence shared by the two molecules that recombine. 
Because the homology regions can be chosen freely, recombineering is not dependent on the 
location of restriction sites and any position on a target molecule can be specifically altered.  
Recombineering is mediated by transient expression of the phage recombinase pairs, either 
RecE/RecT from the Rac prophage (1,11,12) or Redα/Redβ from λ phage (2-5,11-13). RecE 
and Redα are 5′-3′ exonucleases (14,15), and RecT and Redβ are DNA annealing proteins 
(16-18). Linear DNAs, either double-stranded, usually in the form of PCR products, or 
single-stranded synthetic oligonucleotides (19,20) are introduced by electroporation and 
provide the substrates to introduce genetic change adjacent to the region of homologous 
recombination. Interaction between RecE and RecT, or Redα and Redβ, facilitates double 
stranded homologous recombination (11), however, only the annealing protein is required for 
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recombination promoted by single stranded oligonucleotides (19,20). Recombineering is 
convenient because efficient recombination can be achieved with short lengths of perfect 
sequence identity, typically 50 bp or less, and the adjacent regions of non-homology can 
range from 1bp to >50kb (1,12). Hence the homology regions can be easily incorporated into 
PCR primers by oligonucleotide synthesis and virtually any mutation or insertion can be 
achieved. Recombineering is now widely employed to engineer cloned DNA in all commonly 
used vectors (e.g. BACs, fosmids, and plasmids) and several prokaryotic chromosomes. 
Applications include subcloning of precisely defined sections by gap repair (3), 
oligonucleotide-directed mutagenesis (19,20), BAC engineering for gene targeting (21-23), 
high-throughput DNA engineering (24-27), and a variety of other precise applications.  
Seamless mutagenesis refers to site-directed mutagenesis without any other nearby change, 
such as the presence of the selectable gene used to introduce the mutation. Mutagenesis in a 
protein coding region is a clear example of the need for seamless DNA engineering because 
any extraneous sequence introduced during the mutagenic step could interfere with 
expression. Seamless mutagenesis has been achieved using a two-step selection/ 
counterselection strategy, which first involves the replacement of the target site with a 
selectable cassette such as an antibiotic resistance gene accompanied by a counterselectable 
gene. The cassette is then subsequently replaced seamlessly with the desired sequence by 
selecting against the counterselectable gene usually involving the administration of a small 
molecule, such as streptomycin or a sugar (1,28-37). Popular options of counterselectable 
markers include sacB (1,28), rpsL (29-32), as well as markers that can, in the right host 
background, both be selected for and against including galK (33) , thyA (34), and tolC (35).  
Bacterial toxin-antitoxin (TA) systems are based on closely linked genes that together 
encode a protein poison and an antidote. The best characterized TAs operate to maintain 
plasmids. Typically the toxin is stable and the antitoxin is unstable so if the plasmid encoding 
the TA pair is lost, the host will die (38-40). The ccdA and ccdB TA pair was found in the ccd 
(control of cell death) operon of the E. coli F plasmid where it serves to maintain this low 
copy plasmid (41,42), by a mechanism known as post-segregational killing (38-40). Binding 
of CcdB to the GyrA subunit of DNA gyrase blocks the passage of DNA and RNA 
polymerases and leads to double-strand DNA breakage and cell death (43-47). The CcdA 
antidote (72 amino acids) prevents the CcdB toxin (101 amino acids) from inhibiting gyrase 
by forming a tight CcdA-CcdB complex. Upon losing the F plasmid, CcdA is quickly 
degraded by Lon protease so that the concentration of CcdA decreases faster than CcdB, 
leaving free CcdB to bind gyrase and kill the cells (48-50).  
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TA systems have been implemented in several biotechnology applications. Most directly, 
they have been used to maintain plasmids in industrial culture (51,52) and to report ligation 
efficiency through loss of function. The ccdB gene has been used as a counterselectable 
marker in a number of commonly used applications (53-57).  
 
Figure 1. Overview of ccdB counterselection strategy. (A) Strategy for BAC or chromosome 
recombineering using ccdB counterselection. First, pSC101-ccdA-gbaA was transformed into E. coli 
cells. Subsequently, Redα/Redβ and CcdA expression were induced by L-rhamnose and by L-
arabinose respectively. Electro-competent cells were prepared and electroporated with the linear 
targeting molecule containing ccdB-sm (here amp). The ccdB-amp PCR product has two 40 bp 
homology arms to the target molecule. Correct recombinants were obtained after plating on LB plates 
containing ampicillin and L-arabinose, and incubated at 30°C. Keep the expression of CcdA at 30°C 
until the ccdB gene was removed. E. coli cells harboring correct ccdB-amp recombinants and 
pSC101-ccdA-gbaA were grown in LB medium in the presence of ampicillin and L-arabinose at 30°C, 
and induced with L-rhamnose for Redα/Redβ, RecA and Redγ expression. Then, electro-competent 
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cells were prepared and electroporated with another linear targeting molecule or oligo, containing the 
DNA of interest and two same 40 bp homology arms as ccdB-amp PCR product. Stop the expression 
of CcdA and Redα/Redβ (no inducers) at 37°C. Correct recombinants were obtained after plating on 
LB plates (for BAC modification, appropriate antibiotics need to be added, while not for chromosome 
modification) at 37°C. (B) Strategy for multi-copy plasmid recombineering using ccdB 
counterselection. Redα/Redβ expression in GBred-gyrA462 was induced by L-arabinose. Electro-
competent cells were prepared and electroporated with the target multi-copy plasmid together with the 
linear targeting molecule containing ccdB-amp. The ccdB-amp PCR product has two 40 bp homology 
arms to the target plasmid. Correct recombinants were obtained after plating on LB plates containing 
ampicillin. Redα/Redβ expression in GB05-red was induced by L-arabinose. Electro-competent cells 
were prepared and electroporated with the recombinant plasmid together with another linear targeting 
molecule or oligo containing the DNA of interest and two same 40 bp homology arms as ccdB-amp 
PCR product. Correct recombinants were obtained after plating on LB plates containing appropriate 
antibiotics. 
In this paper, we describe the use of ccdB counterselection in combination with 
recombineering for efficient and seamless DNA engineering in E. coli. This two-step 
recombineering procedure first involves the replacement of the target site with a ccdB-
antibiotic resistance gene cassette by selection for antibiotic resistance. The first step needs to 
be performed either with CcdA expression or in a CcdB-resistant E. coli strain, which has the 
gyrA462Arg→Cys mutation. Because counterselection protocols must be different for single or 
multiple copy situations, we describe two versions of the strategy. For single copy targets 
such as BACs or the E. coli chromosome, we put the ccdA gene on our standard 
recombineering expression plasmid. For multi-copy targets we employ stable E. coli strains.  
MATERIALS AND METHODS 
Bacterial strains, plasmids and culturing conditions 
E. coli strains and plasmids used in this work are listed in Supplementary Table 1. E. coli 
strains were maintained in LB medium at 30°C or 37°C, and selected with appropriate 
antibiotics (chloramphenicol [cm], 15 µg/ml; ampicillin [amp], 100 µg/ml; gentamycin 
[genta], 3 µg/ml and tetracycline [tet], 5 µg/ml). The concentration of L-arabinose and L-
rhamnose used for induction was 1.4 mg/ml.  
Recombineering  
Recombineering was performed as previously described by Fu et al. (58). The selection of 
recombinants was carried out depending on the selection marker in the cassette. PCRs were 
performed with Phusion polymerase (New England Biolabs, GmbH, Frankfurt am Main, 
Germany) according to the manufacturer’s protocol. Only lagging oligos were used in the 
counterselection step to achieve higher efficiencies of single strand oligonucleotide repair 
(ssOR) (19,20).  
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Figure 2. Schematic presentation of the plasmids used. (A) p15A-ccdB-amp contains the ccdB-amp 
fusion gene. (B) p15A-rpsL-ccdB contains ampicillin resistance gene (amp), rpsL, gentamycin 
resistance gene (genta) and ccdB. Both A and B carry the p15A replication origin. (C) pSC101-ccdA-
gbaA was constructed from pRedFlp (39). ccdA is expressed from the L-arabinose-inducible BAD 
promoter (PBAD) and redγβαA is expressed from the L-rhamnose-inducible RhaB promoter (PRhaB). (D) 
(i) and (ii) are function test of the cassette of rhaS-rhaR-PRhaB-redγβαA in pSC101-ccdA-gbaA. The 
function test was performed by co-electroporating a linear PCR fragment and a plasmid into L-
rhamnose induced (ii) or uninduced (i) GB2005 cells harboring pSC101-ccdA-gbaA. The linear PCR 
fragment has two 50 bp homology arms to the plasmid. After recovery, 100 μl of culture were plated 
on LB plates supplemented with appropriate antibiotics. The results showed that the function of 
redγβαA is fine and L-rhamnose-inducible RhaB promoter is stringent. (iii) and (iv) are function test 
of the cassette of araC-PBAD-ccdA in pSC101-ccdA-gbaA. The function test was performed by 
electroporating p15A-ccdB-amp into L-arabinose induced (iv) or uninduced (iii) GB2005 cells 
harboring pSC101-ccdA-gbaA. After recovery, 10 μl of culture were plated on LB plates containing 
ampicillin plus L-arabinose (iv) or not (iii) respectively. The results showed that the function of ccdA 
is fine and L-arabinose-inducible BAD promoter is stringent. 
Construction of dual inducible expression plasmid pSC101-ccdA-gbaA  
pSC101-ccdA-gbaA (Figure 1A and Figure 2C) carries the ccdA gene under the control of 
the arabinose-inducible PBAD promoter, and redα, redβ and redγ genes of the λ phage together 
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with the recA gene (redγβαA) in a polycistronic operon under the control of the rhamnose-
inducible PRhaB promoter. In the presence of L-rhamnose, Redα/Redβ expression in E. coli 
cells allows efficient homologous recombination between linear DNA fragments and 
chromosome or BAC. While, in the presence of L-arabinose, CcdA is expressed, conferring 
CcdB resistance to E. coli cells (Figure 1A bottom and Figure 2D).  
pSC101-ccdA-gbaA is a derivative of pSC101 replicon, which is a low copy number (~5 
per cell) and thermo sensitive plasmid. It replicates at 30°C, but not at 37°C (59). 
Consequently, it can be easily eliminated from the host by temperature shift in the absence of 
selection. Since pSC101-ccdA-gbaA is based on pSC101 replicon, it can be propagated in E. 
coli together with BACs and most colE1 origin-derived plasmids.  
Construction of p15A-ccdB-amp (cm) and p15A-rpsL-ccdB  
p15A-ccdB-amp (Figure 2A) and p15A-ccdB-cm were constructed by recombineering. 
They are derivatives of p15A replicon, which contain different resistance genes followed by 
ccdB. They can be used as the template to amplify the ccdB-antibiotic resistance gene 
cassette by PCR reactions. p15A-rpsL-ccdB (Figure 2B) was derived from p15A-ccdB-amp 
by inserting rpsL-genta cassette between ccdB and amp.  
Generation of CcdB-resistant E. coli GBred-gyrA462 strain  
50 pmol mixture of synthetic single-stranded lagging and leading oligos, containing the 
mutation of gyrAArg462Cys (Figure 3A) was electroporated into recombinase induced E. coli 
GB05-red (58). The cells were incubated at 37°C overnight after electroporation. Electro-
competent cells were prepared and electroporated with a test plasmid, p15A-rpsL-ccdB 
(Figure 2B), to fish out the CcdB-resistant E. coli mutant GBred-gyrA462. Finally, the test 
plasmid was cured by adding 500 µg/ml streptomycin into the medium. The recombineering 
efficiency of GBred-gyrA462 was tested using our standard protocol and compared with 
GB05-red and DB3.1 harboring pSC101-BAD-gbaA (60).  
Oligos used for generating GBred-gyrA462 strain are listed below. The homology arm 
sequence is in lowercase. The mutation site is in uppercase and bold, and another two bases 
in underlined uppercase are synonymous mutations designed to reduce mismatch repair.  
gryA1 5’-gtcgagcagtttttcgtgctcaagaccggtcagtttctgcaGGCAcaAatccagaatcgcctgagcttgctgttc 
ggtcaggtagtac-3’  
gyrA2 5’-gtactacctgaccgaacagcaagctcaggcgattctggatTtgTGCCtgcagaaactgaccggtcttgagcac 
gaaaaactgctcgac-3’  
Using ccdB counterselection to modify pBeloBAC11  
The general strategy for BAC or chromosome recombineering using ccdB counterselection 
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is depicted in Figure 1A. Briefly, the dual inducible expression plasmid pSC101-ccdA-gbaA 
was electroporated into E. coli DH10B harboring pBeloBAC11. The linear targeting 
molecule containing ccdB-amp was amplified from BseRI digested p15A-ccdB-amp by PCR 
using oligonucleotides BACccdB-amp1 (5’-aatacgactcactatagggcgaattcgagctcggtacccgTTTG 
TTTATTTTTCTAAATAC-3’) and BACccdB-amp2 (5’-ctcaagcttgcatgcctgcaggtcgactctagag 
gatcccAGCCCCATACGATATAAGTTG-3’).  
As shown in Figure 4A, in the first round of recombineering, the correct recombinant, 
pBeloBAC11-ccdB-amp, was obtained after plating on LB plates containing Amp and L-
arabinose. The resulting recombinants were analyzed by restriction digestion of EcoRI.  
In the second round of recombineering, 50 pmol of synthetic lagging oligos (5’-
ctcaagcttgcatgcctgcaggtcgactctagaggatccccgggtaccgagctcgaattcgccctatagtgagtcgtatt-3’) was 
electroporated. After recovery, the cultures were diluted 100 times and 100 µl was plated on 
LB plates supplemented with Cm, 0.1 mM IPTG and 40 µg/ml X-Gal. The plates were 
incubated at 37°C overnight and the number of colonies was counted.  
Making a single base pair substitution in plu3263 in pBR322 vector  
Two rounds of recombineering were used to introduce a point mutation in plu3263 in a 
pBR322 vector (Figure 5A). The general strategy for multi-copy plasmid recombineering 
using ccdB counterselection is depicted in Figure 1B. Briefly, the target plasmid pGB-
plu3263 together with the PCR products of ccdB-cm, amplified from the BseRI digested 
p15A-ccdB-cm, were coelectroporated into recombinase induced GBred-gyrA462 competent 
cells, which are resistant to CcdB and have the artificial arabinose inducible Red operon on 
the chromosome. The recombinant plasmid pGB-plu3263-PCP3-ccdB-cm was selected on 
LB plates containing Cm and Amp. The correct clones were identified by restriction analysis, 
and transformed into GBred-gyrA462 again to obtain pure population of the recombinants. 
The function of the ccdB gene of these clones was tested by electroporation into the gyrase 
wide type GB2005 strain.  
Oligos used for PCR amplification of the ccdB-cm cassette are listed below. Sequence as 
homology arm for recombineering is in lowercase.  
3263PCP3ccdBcm5 5’-tttgaacaggttggccgacatgacagtttctttgccttgggcggtcacTGTGACGGAA 
GATCACTTCGCAG-3’  
3263PCP3ccdBcm3 5’-ccaatcctatacgccgtaaacgttcgatcatcctgactgccaacagcgTTTGTTCAAA 
AAAAAGCCCGCTC-3’  
In the second round of recombineering, 50 pmol of synthetic single-stranded lagging 
oligos, 3263SPCP3A-B (5’-caggcccaatcctatacgccgtaaacgttcgatcatcctgactgccaacagCGCgtgac 
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cgcccaaggcaaagaaactgtcatgtcggccaacctgttcaaca-3’, the mutation site is in uppercase and bold) 
and the pGB-plu3263-PCP3-ccdB-cm plasmid DNA were co-electroporated into the 
recombinase induced GB05-Red competent cells. The recombinant plasmid pGB-plu3263M 
was screened on LB plates containing Amp. The correct recombinants were identified by 
restriction analysis, following verification by sequencing. Three correct pGB-plu3263M 
clones were subsequently electroporated into E. coli GB05-MtaA (12,61) to check the 
production of luminmides (the products of Plu3263).  
 
Figure 3. Generation of E. coli GBred-gyrA462. (A) Schematic presentation of generation of CcdB-
resistant E. coli GBred-gyrA462. The Arg462-coding codon CGT was changed into Cys-coding 
codon TGC. (B) Comparing the recombineering efficiency of GBred-gyrA462 with GB05-red and 
DB3.1 harboring pSC101-BAD-gbaA. The recombineering was performed by co-electroporating a 
linear PCR fragment and a plasmid into recombinase induced E. coli cells. The linear PCR fragment 
has two 50 bp homology arms to the plasmid. The recombineering efficiency was indicated by the 
colony number on LB plates supplemented with appropriate antibiotics. Results are from three 
independent experiments. Error bars represent the standard deviation. 
Cultivation, extraction and HPLC/MS analysis 
E. coli GB05-MtaA containing pGB-plu3263 or pGB-plu3263M was inoculated from 
overnight cultures (2%) into 5 ml LB medium with Amp in 15 ml glass tubes. The expression 
of Plu3263 was induced with Tet (0.5 μg/ml) at 4 hours after inoculation, the cultures were 
incubated for another 4 hours and 2% of XAD-16 absorber resin was added. The cultures 
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were continued to be incubated at 30°C for 24 hours. The cells and the resin were harvested 
by centrifugation and extracted with acetone and methanol. Solvents were removed in vacuo 
by Genevac, and the residue was dissolved in 500 μl methanol. An aliquot of 5 μl was 
analyzed by HPLC-MS; an Agilent 1100 series solvent delivery system coupled to Bruker 
HCTplus ion trap mass spectrometer. The chromatographic conditions were: RP column 
Nucleodur C18, 125 by 2 mm, 2.5 µm particle size, and precolumn C18, 8×3 mm, 5 µm. 
Solvent gradient (with solvents A [water and 0.1% formic acid] and B [acetonitrile and 0.1% 
formic acid]) from 5% B to 95% B within 20 min, followed by 3 min with 95% B at a flow 
rate of 0.4 ml/min. Detection was carried out in positive and negative ion models. 
 
Figure 4. Point mutation generated in BAC using ccdB counterselection. (A) Schematic presentation 
of using ccdB counterselection to modify pBeloBAC11. (B) The recombineering efficiency of 
different recovery methods in the ccdB counterselection step. The efficiency is indicated by the 
number of blue colonies and white colonies on LB plates. Results are from three independent 
experiments. Error bars represent the standard deviation. (C) A picture of the colonies on the LB plate 
supplemented with Cm, IPTG and X-Gal after ccdB counterselection. About 95% colonies are blue 
and about 5% are white. (D) EcoRI restriction analysis of BAC DNAs from counter-selected blue 
colonies and white colonies. The BAC DNAs from white colonies have the same digestion pattern as 
those from blue colonies. 
RESULTS AND DISCUSSION 
Overall strategy 
The principles of recombineering with ccd counterselection are illustrated in Figure 1. For 
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single copy targets, the ccdA gene is expressed from the same expression plasmid as the Red 
genes for recombineering. In pSC101-ccdA-gbaA, ccdA is expressed from the arabinose--
inducible PBAD promoter and the RedγβαA operon from the rhamnose-inducible PRhaB 
promoter. The plasmid is introduced into a host containing the target followed by arabinose 
and rhamnose induction and electroporation with a ccdB-antibiotic resistance gene cassette 
(here ampicillin) flanked by homology arms for recombineering. After selection for Amp 
resistance, the culture is induced only with rhamnose, electroporated with DNA containing 
the seamless mutation (either double stranded DNA or a single stranded oligonucleotide) and 
maintained at 37°C to eliminate the expression plasmid. Cells that have eliminated the ccdB 
gene will survive, whereas cells that have not will die from CcdB toxicity.  
For multi-copy targets, there is an implicit limitation with counterselection. If a host cell 
contains both the intended product without the counterselectable gene and the parental 
plasmid with the counterselectable gene, it will die under counterselection pressure. In other 
words, the presence of the counterselectable gene is dominant and will occlude recovery of 
the intended product. Hence counterselection with plasmids is best exerted by including a 
transformation step so that each host cell can only harbor a single type of plasmid. To 
incorporate the required transformation step in an optimized counterselection strategy, we 
made a gyrA462 mutation in the recombineering strain, GB05-red, which has the arabinose--
inducible PBAD-RedγβαA operon integrated into the chromosome (58). Shortly before making 
cells for electroporation, GBred-gyrA462 cells are induced with arabinose, then co-
electroporated with the target plasmid and the ccdB-cm cassette flanked by homology arms 
for recombineering. After selection for Cm and plasmid-mediated resistance, plasmids are 
isolated and co-electroporated with DNA containing the seamless mutation (either double 
stranded DNA or a single stranded oligonucleotide) into arabinose induced GB05-red and 
selected for plasmid-mediated resistance. Cells harboring plasmids that have eliminated the 
ccdB gene will survive.  
To achieve methods based on ccdB counterselection, we built pSC101-ccdA-gbaA and 
GBred-gyrA462. The performance of these reagents was verified by functional tests (Figure 2 
and 3). Then we applied the ccdB counterselection strategies to (a) evaluate efficiencies in a 
BAC-based reporter assay; and (b) make a point mutation in a plasmid that we wanted for our 
other research goals.  
Generation of CcdB-resistant E. coli GBred-gyrA462 
We found that recombineering in the gyrA462 strain, E. coli DB3.1 (Invitrogen GmbH, 
Karlsruhe, Germany) was not so efficient. Hence, we introduced gyrA462 into our 
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recombineering-proficient E. coli strain GB05-red by oligonucleotide-directed mutagenesis 
(Figure 3A). The Arg462-coding codon CGT of gyrA was changed into Cys-coding codon 
TGC to create GBred-gyrA462. The recombineering efficiency of GBred-gyrA462 is 
comparable with GB05-red and higher than DB3.1 harboring pSC101-BAD-gbaA (Figure 
3B).  
Using ccdB counterselection to modify pBeloBAC11  
A functional test based on β-galactosidase expression from pBeloBAC11 was used to 
evaluate the efficiency and fidelity of ccdB counterselection for BAC recombineering (Figure 
4A). The lacZ gene of pBeloBAC11 was first disrupted by the ccdB-amp cassette. Then, in 
the second round of recombineering, the ccdB-amp cassette was replaced with an 80nt 
oligonucleotide by counterselection against CcdB. CcdA expression was terminated by 
removing arabinose and culturing at 37°C to eliminate pSC101 replication.  
After counterselection, restoration of the lacZ gene was scored by blue versus white 
colonies on LB plates supplemented with IPTG and X-Gal (Figure 4C). We used this test to 
evaluate the relationship between CcdA removal and CcdB toxicity by employing several 
recovery methods with different parameters (Figure 4B). All variations worked well 
indicating robustness of the method. Although the recombineering efficiency after recovery at 
30°C for 2 hours was a little higher than 37°C for 1 hour, the latter is more convenient.  
After counterselection, about 95% of the colonies on LB plates supplemented with IPTG 
and X-Gal were blue, and only about 5% were white (Figure 4C). We picked 16 white 
colonies and 4 blue colonies for restriction analysis (Figure 4D). Unexpectedly, all 16 white 
clones had the same digestion pattern as the 4 blue clones suggesting that the white clones 
were also successfully repaired but other mutations had been introduced by the synthetic 
oligos.  
Mutation of a single base pair in plu3263 cloned in pBR322  
The luminmide biosynthetic gene plu3263 was identified in the genome sequence of 
Photorhabdus luminescens TT01 DSM15139 (62). It encodes a NRPS (Non-ribosomal 
peptide synthetase) composed of 5 modules. plu3263 was directly cloned into pASK3 vector 
(pBR322 origin, IAB, Gottigen) by using linear plus linear homologous recombination (12) 
to form pGB-plu3263, in which plu3263 is under the control of a tetracycline inducible 
promoter. The luminmides can be produced in E. coli GB05-MtaA (12,61). The invariant 
serine2742 residue (OH group) in the signature sequence (GGD/HSL) of PCP3 domain in 
Plu3263 is the active site for attachment of the 4’-phosphopantetheine cofactor (63), which 
catalyzes the conversion of apo-PCP to holo-PCP. If this serine residue is mutated, the 
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function of PCP3 domain should be completely lost and no luminmides will be produced. 
The serine-coding codon 2742, TCG, was changed to GCG generating S2742A (Figure 5A). 
In the first round of recombineering, a 1 bp deletion was introduced into codon 2742 in 
addition to insertion of the ccdB-cm cassette. In this step, 10 out of 12 random checked 
colonies on the selection plates were shown to be mixtures of pGB-plu3263 and pGB-
plu3263-PCP3-ccdB-cm as expected (data not shown). The recombinant and unmutated 
plasmids were separated by retransformation into E.coli GBred-gyrA462. First we checked 
12 random colonies to find 6 clones of pGB-plu3263-PCP3-ccdB-cm. These were 
electroporated into gyrase wild type E. coli GB2005 to check the function of ccdB gene and 
all 6 clones killed the host indicating that CcdB was expressed as expected.  
pGB-plu3263-PCP3-ccdB-cm was then co-electroporated into GB05-red with an oligo to 
replace the ccdB-cm cassette. We checked 24 colonies and found 15 to be correct (data not 
shown). Like most NRPS genes, plu3263 contains many repeated sequences. The remaining 
9 clones were all due to intramolecular recombination between the repeated sequences. This 
background is inherent to counterselection, because any mutation that ablates expression of 
the counterselectable gene will be selected. Sequencing showed that all 6 pGB-plu3263M 
candidates examined were correctly mutated (Figure 5B). Three correct pGB-plu3263M 
clones were subsequently electroporated into E. coli GB05-MtaA to check for the production 
of luminmides (the products of Plu3263). HPLC-MS analysis showed that the mutations 
abolished luminmide production (Figure 5C).  
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Figure 5. Mutation and expression of luminmide biosynthetic gene plu3263. (A) Schematic 
presentation of making a single base pair substitution in plu3263. The Ser2742-coding codon TCG 
was changed into Ala-coding codon GCG. (B) Sequence analysis of the point-mutation region. All 
clones had the intended substitution (shadow). (C) HPLC-MS analysis (base peak chromatogram 
(BPC), m/z = 200 to 1100 + All MS) of E. coli GB05-MtaA containing pGB-plu3263M (line 1) and 
pGB-plu3263 (line 2). The products of Plu3263, luminmides (Retention Time=18-20 min) were 
completely abolished. 
CONCLUSION 
The development of recombineering has enabled a wide variety of DNA engineering 
applications. Amongst these, methods based on consecutive steps of insertion by selection 
and replacement by counterselection are prominent because they permit seamless 
mutagenesis. Seamless mutagenesis is an ideal DNA engineering goal, so work to develop 
better counterselection applications continue to be developed. We first used sacB for 
counterselection in recombineering (1,28), which is based on addition of a high concentration 
of sucrose. However, sucrose counterselection is often inefficient with false positives 
commonly surviving. Furthermore the sacB gene is present in the vector backbones of 
pBACe3.6 and pTARBAC series, making it unsuitable for use with many BAC constructs. 
To find a better counterselection system we employed rpsL, which conveys sensitivity to 
streptomycin (20). In our hands this is more useful than sacB/sucrose counterselection. Other 
labs have employed other counterselection systems including galK/2-deoxy-
galactose+glycerol (33), thyA/trimethoprim+thymine (34), and tolC/colicin E1 (35). Our 
experience with these counterselection systems indicates that they are not better than 
rpsL/streptomycin and in some cases involve certain inconveniences such as a need for 
special media and/or unusual selection reagents. Use of galK, thyA or tolC requires additional 
knockout steps to generate ΔgalK (33), ΔthyA (34), ΔtolC (35) mutant strains respectively. 
Consequently these counterselection systems are not portable and BACs must be transformed 
into the mutant strains. All these counterselection systems often require experiment-to-
experiment titration to find the optimal concentration of the conditional toxin for the 
counterselection window, which can be quite small.  
Here we explored the merits of a genetic counterselection system based on the ccdA/ccdB 
toxin/antitoxin system. The system is more convenient than a chemical based system and as 
shown in Figure 4, appears to be effective across a wide range of conditions thus reducing the 
need to optimize the counterselection step for each different application. We also developed 
different reagents and protocols for single and multiple copy applications, which may also 
reduce the need to adapt the counterselection window for each experiment. Consequently we 
are confident that counterselection with ccdA/ccdB adds to the recombineering repertoire and 
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will be a helpful improvement. Recently we described an improved method for 
counterselection with oligonucleotides based on the reduction of intramolecular 
recombination at the counterselection step by expression of only Redβ without Redα (32). 
Here again, as with many counterselection applications, we found that intramolecular 
recombination was a prominent source of background (Figure 5). To combine the advantages 
of that method with the ccdA/ccdB method, plasmids and strains are under construction. The 
combination should further improve the general utility of seamless mutagenesis via 
recombineering.  
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Supplementary data 
Supplementary Table S1. Strains and plasmids used in this work 
Strains and 
plasmids 
Genotype or relevant features 
E.coli strains  
   GB2005 (HS996, ∆recET, ∆ybcC). The endogenous recET locus and the DLP12 
prophage ybcC, which encodes a putative exonuclease similar to the Redα, 
were deleted 
   DB3.1 (gyrA462ArgCys, Invitrogen GmbH, Karlsruhe, Germany). Used for 
propagating plasmids containing ccdB 
   GB05-red (GB2005, araC-BAD-αβγA) lambda red operon and recA under BAD 
promoter were inserted at the ybcC locus 
  GBred-gyrA462 (GB05-red, gyrA462) GyrA mutation of Arg462Cys 
  GB05-MtaA (GB2005, mtaA-genta) a pPant transferase MtaA from myxobacterium 
Stigmatella aurantiaca DW4/3-1 was randomly transposed into the 
chromosome 
Plasmids  
  p15A-ccdB-amp p15A replicon. PCR templates to amplify ccdB-amp cassette (plasmid DNA 
digested with BseRI) 
  p15A-rpsL-ccdB p15A replicon. The test plasmid used to generate E.coli GBred-gyrA462 
  pSC101-BAD-
gbaA 
pSC101 replicon. Tetracycline resistance, lambda red operon and recA 
(redγβαA) under BAD promoter 
  pSC101-ccdA-
gbaA 
pSC101 replicon. Tetracycline resistance, ccdA under BAD promoter and 
redγβαA under RhaB promoter 
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Abstract 
Cloning and engineering a natural product biosynthetic pathway combined with robust 
heterologous expression in a tractable host is a proven approach for combinatorial 
biosynthesis of microbial secondary metabolites. Herein, we employ ccdB counterselection 
combined with oligonucleotide-mediated recombineering to efficiently create point mutations 
in a complex NRPS gene plu3236 located on a multi-copy plasmid in E. coli. Targeting the 
active site residues of NRPS A domains, single and double mutations were rationally 
constructed within the Plu3263 A3 domain which is part of a nonribosomal peptide 
synthetase producing luminmides. The mutations lead to an alteration of the predominant 
product from luminmide A in the wild type pathway to luminmide B in several mutants as a 
result of specifically altering the specificity code of the domain. These results demonstrate 
the suitability of counterselection recombineering for site-directed mutagenesis of complex 
NRPS biosynthetic pathways in E. coli and to modify the gatekeeper role of A domains 
resulting in specific alterations of pathway products. 
Introduction 
Nonribosomal peptide synthetases (NRPSs) are large multimodular and multifunctional 
enzymes that specifically bind, activate and condense amino acids to form peptide bonds in a 
template-directed fashion
[1]
. These megaenzymes are responsible for the biosynthesis of 
polypeptides exhibiting a variety of biological activities, such as antibiotics
[2, 3]
, antitumor 
drugs
[4]
, immunosuppressives
[5]
, siderophores
[6]
, and toxins
[7]
. Each NRPS module represents 
a functional building unit required for the recognition and activation of one amino acid 
monomer as well as incorporation into the growing peptide chain through condensation of a 
C-N bond
[8]
. The primary method for combinatorial biosynthesis involves the alteration of 
enzymatic NRPS modules which can lead to a corresponding change in the structural features 
of peptides
[9]
. A NRPS module consists of a minimal set of domains, the peptide bond-
forming condensation (C) domain and the amino acid adenylation (A) domain, as well as a 
phosphopantetheine primed thiolation (T) domain (also known as a peptidyl carrier protein, 
PCP). The adenylation (A) domain that selects and activates specific amino acid from a large 
pool of substrates is the ‘gatekeepers’ of the modular ‘assemble-lines’[8]. Therefore, the 
alteration of an A domain in the assembly line by genetic engineering is a feasible method to 
manipulate the peptide backbone. The crystal structure of a Phe-activating A-domain, 
PheA
[10]
, from gramicidin S synthetase, combined with phylogenetic analysis and in vitro 
biochemical studies classified the 10 active site residues that are responsible for recognition 
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and binding the amino acid substrates as ‘specificity-conferring codes’ or ‘nonribosomal 
code’[11-13]. These codes were derived from characterized A domains, and they also allow us 
to predict the substrate of unknown A domains from their translated nucleotide sequences
[14-
16]
. Moreover, by changing as few as one or two of these active site residues, it has been 
shown that it is possible to switch the specificity of A domains from one amino acid to 
another in vitro (e.g. from L-Phe to L-Leu
[11,17]
, to L-Tyr
[18]
 for GrsA, and from L-Phe to L-
Ala for TycA
[19]
) and in vivo (e.g. from L-Glu to L-Gln for SrfA-A1
[20]
, from L-Asp to L-Asn 
for SrfA-B5
[20]
, from L-Val to L-Leu, L-IIe, L-Ala,  or to L-Phe for AmdK
[21]
, and (2S,3R)-3-
methyl glutamic acid to non-natural (2S,3R)-3-methyl glutamine for CdaPS3
[22]
). The A 
domain was generally engineered in E. coli, and subsequently transferred into the native 
producer to replace the wild type A domain, which is time-consuming and inefficient for 
further genetic manipulation, especially for some slow-growing and genetically intractable 
producers.  
For the genetic engineering of natural product biosynthesis genes, it is important to 
introduce seamless and precise mutations in the sequence of interest, and is particularly 
important for the modification of PKS and NRPS assembly lines, because in some cases even 
the alteration of one base pair could lead to complete loss of products. Considering this, 
subtle modification without any unwanted additional sequence is preferred and can be 
achieved by the selection/counterselection strategy in vivo to remove unexpected mutations 
which may be caused by in vitro site-directed mutagenesis. Counterselection, such as rpsL or 
sacB, in combination with oligonucleotide-mediated recombineering is a high efficient 
approach to introduce single point mutation into plasmids, large bacterial artificial 
chromosomes (BACs) and E. coli chromosomes
[23-26]
. Recently, we reported the employment 
of ccdB as a counter-selection marker for seamless DNA engineering in E. coli. By using this 
ccdB counterselection reombineering strategy, point mutations in BAC and multi-copy 
pBR322 plasmid were successfully created (Chapter 3). 
The luminmide biosynthetic pathway is encoded by plu3263 located in the chromosome of 
entomopathogenic bacterium Photorhabdus luminescens subspecies laumondii strain TT01
[27]
. 
The gene plu3263 was directly cloned by the newly established linear plus linear homologous 
recombination (LLHR) from a genomic DNA and successfully heterologous expressed in E. 
coli GB05-MtaA to elucidate the products luminmides A and B
[28]
 (Table 1). Almost in 
parallel, the same products were also identified by MS and stable isotope labeling from the 
native host and named GameXPeptides A-D
[29]
. Plu3263 is composed of five NRPS modules. 
The first, third, and fourth C domains have been assigned by phylogenetic inference as dual 
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E/C domains. These domains catalyze both epimerization of upstream amino-acyl-S-
pantetheinyl donor and condensation resulting in the presence of the corresponding D-amino 
acids residues in the final products independent of any additional epimerization domains. The 
second standard 
L
CL domain catalyzes the condensation of two L-amino acids giving rise to a 
L-amino acid at the coresponding position within the luminmide backbone. This phylogenetic 
assignment of C domains into sub-classes
[30]
 in general enables the determination of the 
configuration of amino acid residues
[28,31,32]
. This approach should be used, however, with 
caution and should be complemented by traditional chemical methods, such as advanced 
Marfey’s method[33,34], for the determination of the absolute configurations where two or 
more identical amino acids are present in a single cyclic peptide backbone. In the identified 
luminmides/GameXpeptides, the third module (E/C-A3-T) of Plu3263 is responsible for 
activation and incorporation of two different amino acids, Phe and Leu. This suggests broad 
substrate tolerance within both the E/C and A3 domains in this module, as well as, a level of 
substrate tolerance in downstream modules. Guided by specificity-conferring codes, it is 
possible to alter the NRPS substrate specificity and promiscuity, e.g., by changing one or two 
amino residues in the amino acid binding pocket of the A3 domain using counterselection 
recombineering. This approach could result in removing undesirable products or in increasing 
the amount of favored side product.  
 
Scheme 1. Methodfor ccdB counterselection recombineering to create point mutation on plu3263 
construct. A cm
R
-ccdB counterselection cassette is introduced to remove the target nucleotides by 
induction of Redγβα in E. coli DB3.1 and selection on chloramphenicol. Then, the counterselection 
cassette is replaced by oligonucleotides containing a mutation of interest which involved induction of 
tetRampR
plu3263
cmR-ccdB PCR product
Induce Redγβα in DB3.1
and select on Cm
TGT
ATG
ATG
Induce Redγβα in DB3.1, transfer 
into GB2005 and select on Amp
Ptet
Oligonucleotide
plu3263
-cm-ccdB
plu3263*
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Redγβα in E. coli DB3.1 followed by transformation of plasmids into E. coli GB2005 for 
counterselection of correct mutants (see method).  
Herein, five new luminmides were identified in an E. coli heterologous host by using 
HRESIMS, direct and inverse amino acids feeding experiments as well as 2D-NMR. We then 
efficiently created point mutations of the NRPS gene plu3263 in a multi-copy plasmid by 
using ccdB counterselection recombineering (Scheme 1). By subsequent expression of 
Plu3263 mutants in E. coli, we investigated the specificity of A3 domain mutants by 
analyzing the corresponding products of luminmide pathway. The minor product of th wild 
type enzyme luminmide B, was altered to become more prominent in several mutants without 
significant reduction of product yields. One mutant even gave better product titers than the 
wild type. Moreover, the production of main product luminmide A could be deliberately and 
significantly reduced in all the mutants. 
Results and discussions 
Characterization of luminmide analogs 
To obtain further insight into the substrate promiscuity of module 3 in vivo, we aimed to 
identify more luminmide analogs, which may have escaped detection in earlier experiments 
due to low production levels, by using MS fragmentation analysis and isotopes feeding 
experiments. Using detailed comparative LC-HRMS profile analysis between the E. coli 
GB05-MtaA with or without Plu3263, luminmides A (1), B (2) and five minor compounds 
(3-7) with pseudomolecular ion at m/z 602.3911 [M+H]
+ 
had the molecular formula 
C32H51O6N5 (5, calculated C32H52O6N5, 602.3912), m/z 570.3679 [M+H]
+ 
had the molecular 
formula C28H51O5N5S (6, calculated C28H52O5N5S, 570.3684), m/z 538.3961 [M+H]
+ 
had the 
molecular formula C28H51O5N5 (7, calculated C28H52O5N5, 538.3963), m/z 566.4274 [M+H]
+ 
had the molecular formula C30H55O5N5 (4, calculated C30H56O5N5, 566.4276) and m/z 
600.4117 [M+H]
+ 
had the molecular formula C33H53O5N5 (3, calculated for C33H54O5N5, 
600.4119) produced only in the Plu3263-containing culture but lacking in the empty 
expression host (Figure 1A). Compounds 3-7 also belonged to luminmides and are named as 
luminmides C-G, respectively. In the known luminmides or GameXpeptides, the modules 2, 
4, 5 only activate and incorporate Leu into the peptide chain as also supported by the same 
specificity-conferring codes of A domains
[28]
 that shows rigid selectivity. However, module 3 
demonstrates substrate tolerance and can activate and incorporate Phe (1) and Leu (2), 
respectively into final products (Figure 1D, Table 1). Furthermore, the A1 domain is predicted 
to select two amino acids Val and Ile into the cyclic peptide
[28]
 but Val and Leu were reported  
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as incorporated in the structure of GameXpeptides A-D in the native host
[29]
. Thus, the 
structural variation of the compound should be present in the amino acid residue(s) I and/or 
III of the pentaptide (Figure 1D).  
 
Figure 1. Characterization of luminmide derivatives. A) Combined extracted ion chromatograms 
(EICs) in positive mode ionization mode of luminmides (1-7) from extracts of E. coli GB05-MtaA 
containing pGB-Ptet-plu3263. B) The direct feeding of labeled L-Leu, L-Ile and L-Phe to confirm their 
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t/min
7.2
Uninduced
EIC 566
4
EIC 602
5
EIC 570
6
EIC 538
7
EIC 586
1
EIC 552
2
I
A)
B)
C)
control +Ile-15N
+Leu-d3
+Phe-13C6
+6
+6
+9
+1
600.41
606.43
610.19 612.18
600 602 604 606 608 610 m/z
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I II III IV V
1 6.80 D-Val L-Leu D-Phe D-Leu L-Leu
2 6.71 D-Val L-Leu D-Leu D-Leu L-Leu
3 7.14 D-Ile L-Leu D-Phe D-Leu L-Leu
4 7.04 D-Ile L-Leu D-Leu D-Leu L-Leu
5 6.04 D-Val L-Leu D-Tyr D-Leu L-Leu
6 6.38 D-Val L-Leu D-Met D-Leu L-Leu
7 6.41 D-Val L-Leu D-Val D-Leu L-Leu
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presence in luminmide C (3). C) Key correlations of TOCSY (bold lines), HMBC (single-headed 
arrows), and ROESY (double headed arrow) of luminmide C (3). D) The structures of luminmides A-
G (1-7). 
The structures of 3-7 were then determined by HRMS, feeding experiments and 2D-NMR. 
The feeding experiments of labeled Leu, Ile and Phe showed they were present in 3 (Figure 
1B, Figure S1) but these findings contradicts with the proposed structure of GameXpeptide 
B
[29]
 which does not include any Ile. Compound 3 was isolated from E. coli GB05-MtaA 
harboring pGB-Ptet-plu3263. The 
1
H-NMR, and 2D-NMR data (HSQC, HMBC, and TOCSY) 
of 3 indicated that it is composed of one Ile (Figure 1C, Table S1), three Leu and one Phe. 
The mass data and long-range HMBC and ROESY correlations confirmed the positioning 
and connection of residues (Figure 1C). However, our limited material restrained us to assign 
confidently the configuration of C-3 of Ile by chemical methods. In our experiments, it is 
clear that it is Ile rather than Leu that was incorporated by the first module into 3 which is 
also true for compound 4. Here, however, but third amino acid of 4 is Leu which is similar to 
2. Thus, the first module of Plu3263 can activate and incorporate Val or Ile into final 
products. Compound 5 differs from 1 by 16 atomic mass units which is in agreement with the 
addition of a hydroxy group (account for +O) and the retention time of those two compounds 
in HPLC chromatograms show that, 5 is more polar than 1 under reversed phase separation 
conditions (Figure 1A, Figure 1D). The inverse labeling experiment of [U-
12
C]tyrosine, [U-
12
C]valine, and [U-
12
C]leucine in a fully labeled 
13
C medium confirmed the existence of one 
Tyr, one Val, and three Leu into 5 (Figure S3). Combined with comparative MS 
fragmentation pattern, the third amino acid residue Phe in 1 was replaced with Tyr in 5 
(Figure 1D). Similar analysis was employed to determine the amino acid composition of 6 
and 7, and the Phe in 1 is substituted with Met in 6, and with Val in 7, respectively (Figure 
1D, Figure S4 and S5). The incorporation of Met into 7 was also corroborated by a direct 
feeding experiment of 
13
C-labeled and deuterated L-Met (Figure S4). Unsurprisingly, Phe, 
Leu, Tyr, Val and Met can be activated and incorporated into the final product by module 3 
but with different efficiencies. To the best of our knowledge, the activation and incorporation 
of Met is unprecedented in the elucidated NRPS biosynthetic pathways. The absolute 
configurations of α-position of amino acid residues in these luminmides are identical to those 
of corresponding positions in luminmide A because they were biosynthesized by the same 
NRPS Plu3263 (Figure 1).  
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Efficient mutation of a complex NRPS gene by site-directed mutagenesis 
Table 1. Comparison of the specificity-conferring code of the NRPS A domains activating 
Phe/Tyr/Leu/Val  with consensus sequences.
[a]
 
  235 236 239 278 299 301 322 330 331 517 
GrsA Phe D A W T I A A I C K 
TycA Phe D A W T I A A I C K 
BacC-M2 Phe D A F T V A A V C K 
CepA Tyr D A S T V A A V C K 
TycC Tyr D A L T T G E V V K 
GrsA*
[b]
 Leu D A W M I G A I C K 
SrfAA-M2 Leu D A F M M G M V F K 
CssA-M9 Val D A W M F A A V L K 
GrsB Val D A F W I G G T F K 
Plu3263-M2/4/5 Leu D A W C I G A V C K 
Plu3263-M3 Phe/Leu D A W C I A A V C K 
[a] Residue numbering according to the GrsA L-phenylalanine activating A domain
[10]
. 
[b] The mutated GrsA which is a L-Leucine activating A domain
[11]
. 
Our next goal was to rapidly switch the active site residues in the building pocket of an A 
domain and monitor the alteration of end products generated by the mutants in vivo. We 
engaged counterselection-based recombineering to introduce seamless site-directed mutations. 
Generally, two selections after consecutive homologous recombination were required for 
accomplishment of seamless plasmid mutagenesis: the positive selection for antibiotic 
resistance to replace the target sequences by insertion of a dual selection-counterselection 
cassette, and the counterselection of the toxicity marker inferred by the counterselectable 
gene for substitution of this cassette with sequences of interest. Here we use a 
chloramphenicol resistance gene (cm
R
) as positive selectable marker and ccdB as a 
counterselectable gene that is only propagated in the gyrA462 E. coli strain DB3.1
[35-37]
 but 
cannot propagated in our standard recombineering E. coli strain GB2005
[38, 39]
. Thus, the first 
step for replacement of target sequences with ccdB-cm cassette is performed in DB3.1 
containing Redγβα expression plasmid pSC101-PBAD-gba
[40]
 for an efficient recombination 
reaction (Scheme 1). In the second step, the oligonucleotide-mediated recombineering is 
accomplished in DB3.1 containing Redγβα to form the mixture of repaired (minority) and 
unrepaired constructs in one cell because of the presence of pBR322 derived multi-copy 
plasmids. ccdB counterselection was achieved by transferring the resultant plasmid mixture 
from DB3.1 into GB2005 to separate the mixture and remove the unrepaired ccdB-containing 
plasmids. The correct mutants should yield viable GB2005, due to the absence of ccdB. 
However, this did not assure the correctness of mutants due to the possibility of 
intramolecular recombinations that removed ccdB and enabled GB2005 to survive. Using this 
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procedure of counterselection through changing host, even one copy of the correct repaired 
plasmid can be selected and therfore proves an effective means for generating point 
mutations in a multi-copy plasmid. 
 
Figure 2. HPLC analysis (base peak chromatogram (BPC) from 530-620 Da in positive ionization 
mode) of the luminmides in E. coli GB05-MtaA containing Plu3263 WT (dashed line) and mutant 
A301G (solid line).The luminmides A-G (1-7) are shown. 
In order to select residues for mutagenesis, we compared the ‘specificity-conferring code’ 
of A3 domain with A domains known to activate Leu, Phe, Val by amino acid alignment 
(Table 1). The nonribosomal code at position 278 is show almost exclusively Met in Leu/Val-
activating A domains while it is Thr when Phe is exclusively recognized. In the Plu3263 A3 
domain, the residue at 278 is Cys. The initial idea was to change Cys278 to Thr, or Met to 
increase the yields of luminmide A or B, respectively. At the residue 301 of the Leu-activating 
domain is Gly, but in Plu3263 A3 domain is Ala. It is proposed to increase the activation 
efficiency of Leu or decrease that of Phe by switching Ala301 to Gly. Furthermore, most of the 
residues in position 299 for activation of Val/Leu/Phe are Phe or Ile, but in Plu3263 A3 domain 
Ile is found, thus the mutation I229F was performed in one round with A301G in a single 
recombineering exercise which was possible due to the vicinity of 299 and 301 amino acid 
residues. We speculated that these single and/or double mutants would improve the catalytic 
efficiency of A3 domain towards Leu or Phe which might lead to variation of luminmides. 
Single mutations C278M, C278T, I299F, A301G, and double mutation I299F/A301G were 
constructed in one round of selection and counterselection recombineering exercises. We then 
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used the C278M construct to generate double mutation C278M/A301G using a second round of 
recombineering (Table S1). Seamless site-directed mutagenesis of a complex NRPS biosynthetic 
pathway in a multi-copy plasmid using ccdB counterselection recombineering was achieved. 
The final efficiency of obtaining the correct recombinant was on average 15% (Table S2), which 
is reasonable considering the iterative nature of modules/domains in large NRPS biosynthetic 
genes which explains the presence of numerous highly homologous stretches of DNA. The 
mutation position in the middle of the repetitive NRPS genes would thus frequently induce 
intramolecular recombination that can result in the deletion of the ccdB cassette and the 
surrounding DNA to generate incorrect recombinants and hinder the efficiency of 
counterselection
[23]
. The incorrect mutants in this investigation are the result of intramolecular 
recombination between the upstream regions (module 1 and 2) and downstream areas (module 4 
and 5) of module 3 as supported by restriction digestion examination.  
Table 2. The yields of luminmides in WT and mutated Plu3263 
[a]
 
 Mutants 
Yields (µg  L
-1
) 
1 2 3 4 5 6 7 
WT 694.5 303.9 87.5 30.1 11.6 8.1 8.9 
C278M 2.7 261.2 
 
23.5 
  
22.7 
C278T 229.9 138.9 26.1 11.3 7.1 1.6 1.6 
I299F 105.4 198.9 8.3 16.3 
 
1.7 7.4 
A301G 17.2 515.2 0.68 53.9 
 
14.8 0.42 
I299F/A301G 4.7 417.2 
 
39.9 
 
11.4 0.25 
C278M/A301G 
 
386.9 
 
38.5 
 
3.4 
 
[a] The yields of luminmides were average of two or three independent clones 
(Table S2) in the same cultivation conditions and were determined by UPLC-
HRMS, and yield less than 0.1 µg L
-1
 was not shown in the table. 
Alteration of luminmide derivatives 
The WT and mutated Plu3263 were expressed in the heterologous host E. coli GB05-
MtaA and the yields of luminmide derivatives were determined by UPLC-HRMS (Table 2). 
The total yields of luminmides in WT Plu3263 were higher than in all of the modified 
mutants, which showed that all the point mutations lower the efficiency of module 3 to 
activate and incorporate amino acid residues. This finding is quite normal for complex NRPS 
biosynthetic pathways that have been genetically manipulated for combinatorial biosynthesis. 
However, the yield of luminmide B showed a significant increase from 304 µg L
-1
 in WT 
Plu3263 to 515 µg L
-1 
in mutant A301G (Figure 3, Table 2, Figure S6), while  the original 
dominant product luminmide A decreased to different extents in all the given mutants, and 
even disappeared in double mutant C278M/A301G. Thus, we can specifically increase the 
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yields of expected compounds by simple single or double mutations in the active site residues 
of the A domain. Besides, the productions of several minor derivatives are also increased by 
1~2 fold (Table 2). For example, the increase of 7 from 9 µg L
-1 
to 23 µg L
-1
 in the mutant 
C278M is consistent with our anticipation that Met in position 278 is advantageous for 
recognition of Val. But C278T did not show any increase of luminmide A as expected 
because the Cys in this position maybe more efficient in this NRPS although in position 278 
Thr is found in all the other Phe-activating A domains. The production of 6 is also increased 
in the mutant A301G (from 8 µg L
-1
 to 15 µg L
-1
) and I299F/A301G (to 11.4 µg L
-1
) and 
shows same trend with luminmide B. This fact implies that the ‘specificity-conferring code’ 
of a Met-activating A domain (6) would be similar to a Leu-activating A domain. Conpound 
3 and 4 changed simultaneously with luminmide A (1) and B (2), respectively, because third 
amino acid residues are identical, Phe in 1 and 3 and Leu in 2 and 4. The differences between 
the pairs 1, 2, and 3, 4, are found in the first amino acid residue, Val in 1 and 2, but Ile in 3 
and 4 (Table 1). 
Table 3. The specificity of Plu3263 A3 domain in vivo 
[a]
  
 Mutants   
Proportion (%)
[b]
 
Phe  Leu  Tyr  Met  Val  
WT 68.3  29.2  1.01  0.71  0.78  
C278M  0.88  91.8  
  
7.32  
C278T  61.5  36.0  1.71  0.39  0.39  
I299F  33.6  63.7  
 
0.51  2.19  
A301G  2.96  94.5  
 
2.46  0.07  
I299F/A301G  0.99  96.6  
 
2.4  0.05  
C278M/A301G  
 
99.2  
 
0.8  
 [a] The values show percentages of defined amino acids 
incorporated, with the sum of all final luminmides as 100%.  
[b] Proportions of less than 0.05% are not shown in this table. 
The reduced overall efficiency of Plu3263 with mutated A domain was complemented by 
the improvement of the specificity and selection for activating and processing specific amino 
acid residues. We calculated the percentage of certain amino acids (at the third residue) in 
comparison to total yields of luminmides to represent the ‘specificity of A3 domain in vivo’ 
regardless of the efficiency (Table 3). Because 1 and 2 as well as 3 and 4, contain the same 
amino acid in the third position, Leu and Phe, respectively, the yields of Leu- and Phe-
luminmides should be the sum of each pair. The WT A3 domain in the heterologous host 
preferentially ‘activates’ (as measured by final product thus representing activation and 
incorporation) Phe (68.2%), and Leu (29.2%). The C278T mutant showed a similar 
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specificity to the WT, but the remaining mutants are favorable to ‘activation’ of Leu. The 
effectiveness of Leu activation in the I299F mutant is 64%, 92% in C278M, 94% in A301G, 
96.5% in the double mutant I299F/A301G, and 99.2% in C278M/A301G (Table 3). In the 
latter double mutant, the Phe-luminmides were completely abolished and only a trace amount 
of 6 was produced in which the third amino acid is Met. In the C278M mutant, the A3 
domain preferentially activates Val rather than Phe. Our strategy also represents a feasible 
way to remove the predominant WT compound and/or improve the yield of a minor product, 
which can simplify the downstream purification procedure of low-level secondary 
metabolites. In this case, the luminmides have a tendency to precipitate out of the solutions 
when the crude extract and fractions are concentrated. It is consequently difficult to purify the 
minor product 2 from the WT Plu3263 extracts. By using the mutant culture, the pure 
compound can be wasily obtained for use in further studies
[28]
.  
Luminmide A only shows weak cytotoxicity against HCT-116 human colon carcinoma 
(IC50=27.5 µg/mL) while luminmide B has no effect on cell viability at concentration as high 
as 100 µg/mL. The planar structure of luminmide A is identical to sansalvamide A peptide 
(against HCT-116, IC50=0.98 µg/mL)
[41]
 which  was regarded as an excellent lead for treating 
multiple cancers
[42-53]
 and it was a chemically synthesized derivative of fungal secondary 
metabolite sansalvamide A (against HCT-116, IC50=9.8 µg/mL)
[54]
 whose the residue V is a 
leucic acid. However, the sansalvamide A peptide contains five L-configured amino acids and 
the cytotoxicity is much higher than luminmide A which contains mixed L- and D-configured 
amino acids (Figure 1D). 
Conclusion 
Combinatorial biosynthesis in a well-established heterologous host is in theory a powerful 
technique. However, still many challenges remain for generating new derivatives of complex 
NRP or PKs natural products
[55]
. We have been able to create single or double point 
mutations efficiently in a complex NRPS in E. coli in vivo by using ccdB counterselection 
recombineering. This method yielded much less unexpected mutations than may be obtained 
by PCR or other in vitro method for performing site-directed mutagenesis. As a result of the 
point mutations in the specificity-conferring code of the NRPS A domains, the WT minor 
product luminmide B (29%) became more abundant (more than 90%) in several mutants 
without significant reduction of product yields, while one mutant (A301G) produced higher 
yields than wild type. The successful in vivo site-directed mutagenesis of an exogenous 
NRPS, encoded on a multi-copy plasmid, combined with robust heterologous expression 
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provides a rational way to generate expected or predictable derivatives based on structural 
biology and bioinformatics.  
Experimental section 
Feeding experiments: E. coli GB05-MtaA/pGB-Ptet-plu3263
[28]
 was cultivated in Luria-
Bertani (LB) broth supplemented with 50 μg mL-1 ampicillin and 1 µg mL-1 gentamicin. For 
direct feeding experiments, L-valine-d8 (Deutero GmbH), L-leucine-5,5,5-d3 (Deutero GmbH), 
L-phenylalanine-ring-
13
C6 (Cambridge Isotope Laboratories, Inc.), L-isoleucine-
15
N (Sigma-
Aldrich), L-methionine-(methyl-
13
C) (Cambridge Isotope Laboratories, Inc.) and L-
methionine (methyl-d3) (Sigma-Aldrich) (final concentration 1 mg mL
-1
) were dissolved into 
LB medium supplemented with suitable antibiotics and sterilized by syringe filter (0.2 µm), 
respectively. The media was inoculated with 2% overnight culture of E. coli GB05-
MtaA/pGB-Ptet-plu3263 and cultivated at 30 °C for 4 h, induced by tetracycline (0.5 µg mL
-1
) 
and 2% adsorber resin Amberlite XAD-16 was added 8 h later. L-phenylalanine, L-tyrosine, 
and L-methionine (Synopharm GmbH & Co. KG, final concentration 4 mg mL
-1
) were 
inversely fed into E. coli cultures grown in [U-
13
C] medium and filter sterilized. Fifty 
milliliters of [U-
13
C] medium was prepared from 0.5 g ISOGRO
®
-
13
C powder (Sigma-
Aldrich) and supplemented 0.9 mL of 100 g L
-1
 K2HPO4, 1.4 mL of 50 g L
-1
 KH2PO4, 1.0 mL 
of 50 g L
-1
 MgSO4 and 15.0 µL of 37 g L
-1
 CaCl2 solutions according to the manufacturer’s 
protocol. The E. coli overnight preculture was washed twice with [U-
13
C] medium prior to 
inoculation into [U-
13
C] medium. Extraction and HPLC/MS analysis of luminmides are same 
as quantitative analysis method. 
Isolation of luminmide C (3): The overnight E. coli GB05-MtaA/pGB-Ptet-plu3263
[28]
 
culture was inoculated in LB medium in the presence of 50 μg mL-1 ampicillin and 2% XAD-
16 adsorber resin (added 8 h later) at 30 °C for 30 hours in shaking flasks. The XAD was 
separated from the supernatant by sieving, washed with dH2O twice and extracted stepwise 
with ethyl acetate, acetone and methanol. The resulting extracts were analyzed by LC/MS 
and most of the compounds were present in the methanol extract. Then, this extract was 
partitioned with equal volume ethyl acetate and dH2O to obtain 0.85 g extract from ethyl 
acetate phase. The extract was loaded onto a Sephadex LH-20 column with methanol as 
mobile phase. Fractions containing significant amounts of 3 were combined and evaporated 
to dryness. Further purification was performed on repeated semi-preparative HPLC 
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instrument equipped with UV detector (220 nm, and 280 nm). A RP-C12 column (Jupiter, 
Proteo 90A, 250 × 10 mm, 4 μm) was used for further purification with a solvent system 
consisting of water (A) containing 0.05% TFA and acetonitrile (B). The gradient was as 
follows: 0-5 min 50% B, 5-15 min 50-70% B, 15-40 min 70% B. Around 0.3 mg luminmide 
C (3) was afforded at the retention time of 32.2–33.2 min as a white solid. The luminmide C 
was dissolved into DSMO-d6 for NMR recording. NMR spectra were recorded on a Bruker 
Ascend 700 MHz spectrometer equipped with a CryoProbe system. The samples were 
measured in DMSO-d6, and the solvent peak was used for spectra calibration (δC 39.51, δH 
2.50 ppm). Data acquisition, processing, and spectral analysis were performed with TopSpin 
3.0 (Bruker BioSpin).  
ccdB counterselection recombineering 
Introduction of counterselection cassette cm
R
-ccdB into site of interest: By 
electroporation, Red/ET recombination expression plasmid pSC101-PBAD-gba-tet
[40]
 combined 
with targeted construct pGB-Ptet-plu3263 were cotransformed into E. coli DB3.1 (Invitrogen) 
competent cells, and 500 µL recovery culture was spread on LB agar containing 5 μg mL-1 
tetracycline and 100 μg mL-1 ampicillin. Restriction analysis was performed to confirm both of 
them. The PCR products mixture of ccdB gene amplified from p15A-Amp-ccdB and 
chloramphenicol resistance gene were cotransformed into L-arabinose induced DB3.1 cells 
bearing pSC101-PBAD-gba-tet and pGB-Ptet-plu3263. All the cells were spread on LB plates 
containing 30 µg mL
-1
chloramphenicol and 100 μg mL-1 ampicillin. The resulting constructs 
were checked by restriction analysis. Generally, all of clones were a mixture of the original 
plasmid and the plasmid containing cm
R
-ccdB cassette. One more transformation into DB3.1 
was required to separate the plasmids and obtain a pure construct pGB-Ptet-plu3263-ccdB-Cm 
construct. Then, four independent plasmids were transformed into GB2005
[38, 39]
 and selected on 
ampicillin LB plates to check the function of ccdB gene. If a few colonies (generally less than 10) 
on the LB plate, this indicates that CcdB works well. It is unusual to see no colonies on the plate 
due to spontaneous intermolecular recombination or mutation may be happened to make the 
ccdB deletion or malfunction.  
Recombination of an oligonucleotide containing a mutation of interest to replace 
counterselection cassette: The DB3.1 strain carrying pure and functional constructs pGB-
Ptet-plu3263-ccdB-Cm were transformed with pSC101-PBAD-gba-tet plasmids. Initial 
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restriction analysis was performed to check both of constructs. Then the single strand 
oligonucleotide (Table 4) with a mutation of interest were transformed into the L-arabinose 
induced DB3.1 electracompetent cells harboring pSC101-PBAD-gba-tet
[40]
 and pGB-Ptet-
plu3263-ccdB-Cm. After 1h at 37 °C shaking for recovery, each 1 mL recovery culture was 
divided into two parts and the same volume LB medium containing 100 μg mL-1 ampicillin was 
added and returned to shake for another 3 h. The plasmid DNA was extracted, resuspended into 
5 μL ddH2O, and 2 μL solution was transformed into GB2005 electrocompetent cells. All the 
cells were plated on the LB plate containing 100 μg mL-1 ampicillin. The plasmid with ccdB can 
kill the normal E. coli strain GB2005 by binding to the gyrase
[56]
. Restriction analysis and 
sequencing were used to verify the mutated regions and recombination arms. The correct 
mutants were transformed into E. coli GB05-MtaA
[28]
 to check the yields of luminmides. A list 
of primers used for mutagenesis is presented in Table 4. 
 
Table 4. Oligonucleotides used for mutagenesis in this work.
[a]
 
Primer names Sequence of primers(5’3’) 
cm
R
-ccdB cassette 
A3-278cm5 TCCACAGCGCCTTTGGCGTTACCTGGAAGAGCAGGCGATAACCCATGCCTGTGAC
GGAAGATCACTTCG 
3263ccd5 GCGTAAAGGAGGTCAGATTATGCAGTTTAAGGTTTACACC 
3263ccd3 TATCGCCGGTAAATCGGTGCCGTCATGAAACATAGCCGGTGTCAATTTGTTCAAA
AAAAAGCCCGCTC 
A3-299Cm5 TGACGGCACCGATTTACCGGCGATAGCGATAAAACCAACCTTATGTGACGGAAGA
TCACTTCG 
A3-301ccdB3 CGGCTGCACAGTGCCTGAAATAGCGCGGGACTCGGCGCTTCTCCTTTGTTCAAAA
AAAAGCCCGCTC 
Repair oligos 
C278ToligB TATCGCTATCGCCGGTAAATCGGTGCCGTCATGAAACATAGCCGGTGTCAAGGTG
GCATGGGTTATCGCCTGCTCTTCCAGGTAACGCCAAAGGCGCTGTGGA 
C278MoligB TATCGCTATCGCCGGTAAATCGGTGCCGTCATGAAACATAGCCGGTGTCAACATG
GCATGGGTTATCGCCTGCTCTTCCAGGTAACGCCAAAGGCGCTGTGGA 
I299F-B 
 
CGGCTGCACAGTGCCTGAAATAGCGCGGGACTCGGCGCTTCTCCTGCAAAGAATA
AGGTTGGTTTTATCGCTATCGCCGGTAAATCGGTGCCGTCATGAAACA 
A301G-B 
 
TCGGCCCGGCTGCACAGTGCCTGAAATAGCGCGGGACTCGGCGCTTCTCCACCAA
ATATTAAGGTTGGTTTTATCGCTATCGCCGGTAAATCGGTGCCGTCATGA 
299-301Mut 
 
ATCGGCCCGGCTGCACAGTGCCTGAAATAGCGCGGGACTCGGCGCTTCTCCACCA
AAGAATAAGGTTGGTTTTATCGCTATCGCCGGTAAATCGGTGCCGTCATGAAACA 
Sequencing 
3263A3seq TGACTCCTCCGGTATAATCG 
[a] Underlined sequences are homology arms for Red/ET recombination. The bold bases represent 
mutated amino acid. 
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Quantitative analysis of luminmides: The E. coli strains harboring the wild type and 
mutated luminmide biosynthetic genes (plu3263) were incubated in 15 mL glass tubes 
containing 5 mL LB plus ampicillin and gentamicin. The culture was inoculated from an 
overnight culture (1:50) and incubated for 4 hours at 30 °C, shaking at 150rpm. After 
induction with tetracycline (final concentration 0.5 µg mL
-1
, water as control), the culture was 
incubated for a further 8 hours and 2% of adsorber resin Amberlite XAD-16 was added, then 
cultivated for 1 day. The resin and biomass were harvested by centrifugation and then 
extracted with 0.37 mL acetone and 1 mL methanol. 1 mL extracts were evaporated to 
dryness and dissolved in 350 µl methanol to form 10× crude extracts. High-resolution mass 
spectrometry (HRMS) was performed on an Accela UPLC-system (Thermo-Fisher) coupled 
to a linear trap-FT-Orbitrap combination (LTQ-Orbitrap), operating in positive ionization 
mode. The 10× crude extracts were separated on a Waters BEH RP-C18 column (50 × 2 mm; 
1.7 mm particle diameter; flow rate 0.6 mL min
-1
), with a mobile phase of water/acetonitrile 
each containing 0.1% formic acid, using a gradient from 5%–95% acetonitrile over 9 min. 
The UPLC-system was coupled to the LTQ-Orbitrap by a Triversa Nanomate (Advion), a 
chip-based nano-ESI interface. A standard curve was established from serial dilutions of 
luminmide A down to 0.15 µg mL
-1
. The yield of luminmide A was determined from the 
peak area (base peak chromatogram) by reference to the standard curve and estimates of the 
yields of all other derivatives were obtained by comparison of the peak areas to those of 
luminmide A.   
Cytotoxicity assay: Human HCT-116 colon carcinoma cells (DSMZ, ACC 581) were 
seeded at 6×10
3
 cells per well in 96-well plates in 180 μL complete medium and directly 
treated with varying concentrations of the compounds. Each sample was tested in duplicate 
along with an internal methanol control. After 5 d incubation, 20 μL of 5 mg/mL MTT 
(Thiazolyl blue tetrazolium bromide) in PBS was added per well and it was further incubated 
for 2 h at 37°C. The medium was then discarded and cells were washed with 100 μL PBS 
before adding 100 μL 2-propanol/10 N HCl (250 : 1) in order to dissolve formazan granules. 
The absorbance at 570 nm was measured using a microplate reader (EL808, Bio-Tek 
Instruments Inc.), and cell viability was expressed as percentage relative to the respective 
methanol control. IC50 values were obtained by sigmoidal curve fitting on logarithmic scale. 
Acknowledgement 
B. Publications 
67 
 
We thank J. Herrmann and T. Hoffmann from R.M.’s laboratory for bioactivity tests and 
high-resolution MS measurements, respectively. Research in the laboratory of R.M. was 
funded by the DFG and BMBF. Y.Z. from Gene Bridges was partially funded by the BMBF 
(MiPro). X.B. thanks China Scholarship Council (CSC) for a PhD fellowship. 
Keywords:  luminmide · point mutation · Red/ET recombineering · biosynthesis · natural 
products 
References 
 [1] M. A. Marahiel, T. Stachelhaus, H. D. Mootz. Chem. Rev. 1997, 97(7), 2651-2674. 
 [2] A. M. A. van Wageningen, P. N. Kirkpatrick, D. H. Williams, B. R. Harris, J. K. 
Kershaw, N. J.  Lennard, M. Jones, S. J. M. Jones, P. J. Solenberg. Chem. Biol. 1998, 5, 
155-162. 
 [3] V. Miao, M. F. Coeffet-LeGal, P. Brian, R. Brost, J. Penn, A. Whiting, S. Martin, R. 
Ford, I. Parr, M. Bouchard, C. J. Silva, S. K. Wrigley, R. H. Baltz. Microbiology 2005, 
151(Pt 5), 1507-1523. 
 [4] L. Du, C. Sanchez, M. T. Chen, D. J. Edwards, B. Shen. Chem. Biol. 2000, 7, 623-642. 
 [5] G. Weber, E. Leitner. Curr. Genet. 1994, 26(5-6), 461-467. 
 [6] C. Pelludat, A. Rakin, C. A. Jacobi, S. Schubert, J. Heesemann. J. Bacteriol. 1998, 
180(3), 538-546. 
 [7] J. D. Walton. Phytochemistry 2006, 67(14), 1406-1413. 
 [8] M. A. Fischbach, C. T. Walsh. Chem. Rev. 2006, 106(8), 3468-3496. 
 [9] S. A. Sieber, M. A. Marahiel. Chem. Rev. 2005, 105(2), 715-738. 
 [10]  E. Conti, T. Stachelhaus, M. A. Marahiel, P. Brick. EMBO J. 1997, 16(14), 4174-
4183. 
 [11]  T. Stachelhaus, H. D. Mootz, M. A. Marahiel. Chem. Biol. 1999, 6, 493-505. 
 [12]  G. L. Challis, J. Ravel, C. A. Townsend. Chem. Biol. 2000, 7(3), 211-224. 
 [13]  H. von Döhren, R. Dieckmann, M. Pavela-Vrancic. Chem. Biol. 1999, 6(10), R273-
R279. 
 [14]  M. Z. Ansari, G. Yadav, R. S. Gokhale, D. Mohanty. Nucleic Acids Res. 2004, 
32(Web Server issue), W405-W413. 
 [15]  B. O. Bachmann, J. Ravel. Meth. Enymol. 2009, 458, 181-217. 
 [16]  C. Rausch, T. Weber, O. Kohlbacher, W. Wohlleben, D. H. Huson. Nucleic Acids Res. 
2005, 33(18), 5799-5808. 
 [17]  C. Y. Chen, I. Georgiev, A. C. Anderson, B. R. Donald. Proc. Natl. Acad. Sci. USA 
2009, 106(10), 3764-3769. 
 [18]  B. W. Stevens, R. H. Lilien, I. Georgiev, B. R. Donald, A. C. Anderson. 
Biochemistry-US 2006, 45(51), 15495-15504. 
 [19]  B. Villiers, F. Hollfelder. Chem. Biol. 2011, 18(10), 1290-1299. 
B. Publications                                                             
68 
 
 [20]  K. Eppelmann, T. Stachelhaus, M. A. Marahiel. Biochemistry-US 2002, 41(30), 9718-
9726. 
 [21]  B. S. Evans, Y. Chen, W. W. Metcalf, H. Zhao, N. L. Kelleher. Chem. Biol. 2011, 
18(5), 601-607. 
 [22]  J. Thirlway, R. Lewis, L. Nunns, N. M. Al, M. Styles, A. W. Struck, C. P. Smith, J. 
Micklefield. Angew. Chem. Int. Ed. 2012, 51(29), 7181-7184. 
 [23]  A. W. Bird, A. Erler, J. Fu, J. K. Heriche, M. Maresca, Y. Zhang, A. A. Hyman, A. F. 
Stewart. Nat. Methods 2011, 9(1), 103-109. 
 [24]  R. Heermann, T. Zeppenfeld, K. Jung. Microb. Cell Fact. 2008, 7. 
 [25]  Y. Zhang, J. P. Muyrers, J. Rientjes, A. F. Stewart. BMC Mol. Biol. 2003, 4(1), 1. 
 [26]  Y. Zhang, F. Buchholz, J. P. Muyrers, F. A. Stewart. Nat. Genet. 1998, 20, 123-128. 
 [27]  E. Duchaud, C. Rusniok, L. Frangeul, C. Buchrieser, A. Givaudan, S. Taourit, S. Bocs, 
C. Boursaux-Eude, M. Chandler, J. F. Charles, E. Dassa, R. Derose, S. Derzelle, G. 
Freyssinet, S. Gaudriault, C. Medigue, A. Lanois, K. Powell, P. Siguier, R. Vincent, V. 
Wingate, M. Zouine, P. Glaser, N. Boemare, A. Danchin, F. Kunst. Nat. Biotechnol. 2003, 
21(11), 1307-1313. 
 [28]  J. Fu, X. Bian, S. Hu, H. Wang, F. Huang, P. M. Seibert, A. Plaza, L. Xia, R. Müller, 
A. F. Stewart, Y. Zhang. Nat. Biotechnol. 2012, 30(5), 440-446. 
 [29]  H. B. Bode, D. Reimer, S. W. Fuchs, F. Kirchner, C. Dauth, C. Kegler, W. Lorenzen, 
A. O. Brachmann, P. Grün. Chem. Eur. J. 2012, 18(8), 2342-2348. 
 [30]  C. Rausch, I. Hoof, T. Weber, W. Wohlleben, D. H. Huson. BMC Evol. Biol. 2007, 7, 
78-92. 
 [31]  J. M. Crawford, C. Portmann, R. Kontnik, C. T. Walsh, J. Clardy. Org. Let. 2011, 
13(19), 5144-5147. 
 [32]  S. W. Fuchs, A. Proschak, T. W. Jaskolla, M. Karas, H. B. Bode. Org. Biomol. Chem. 
2011, 9(9), 3130-3132. 
 [33]  K. Fujii, Y. Ikai, T. Mayumi, H. Oka, M. Suzuki, K. Harada. Anal. Chem. 1997, 
69(16), 3346-3352. 
 [34]  K. Fujii, Y. Ikai, H. Oka, M. Suzuki, K. Harada. Anal. Chem. 1997, 69(24), 5146-
5151. 
 [35]  P. Bernard, M. Couturier. J. Mol. Biol. 1992, 226(3), 735-745. 
 [36]  P. Bernard, K. E. Kezdy, L. Vanmelderen, J. Steyaert, L. Wyns, M. L. Pato, P. N. 
Higgins, M. Couturier. J. Mol. Biol. 1993, 234(3), 534-541. 
 [37]  T. Miki, J. A. Park, K. Nagao, N. Murayama, T. Horiuchi. J. Mol. Biol. 1992, 225(1), 
39-52. 
 [38]  J. Fu, S. C. Wenzel, O. Perlova, J. Wang, F. Gross, Z. Tang, Y. Yin, A. F. Stewart, R. 
Müller, Y. Zhang. Nucleic Acids Res. 2008, 36(17), e113. 
 [39]  J. Fu, M. Teucher, K. Anastassiadis, W. Skarnes, A. F. Stewart. Methods Enzymol. 
2010, 477, 125-144. 
B. Publications 
69 
 
 [40]  J. Wang, M. Sarov, J. Rientjes, J. Fu, H. Hollak, H. Kranz, W. Xie, A. F. Stewart, Y. 
Zhang. Mol. Biotechnol. 2006, 32(1), 43-53. 
 [41]  W. Gu, S. S. Liu, R. B. Silverman. Org. Lett. 2002, 4(23), 4171-4174. 
 [42]  K. Otrubova, T. J. Styers, P. S. Pan, R. Rodriguez, K. L. McGuire, S. R. McAlpine. 
Chem. Commun.  2006, (9), 1033-1034. 
 [43]  K. Otrubova, G. Lushington, D. V. Velde, K. L. McGuire, S. R. McAlpine. J. Med. 
Chem. 2008, 51(3), 530-544. 
 [44]  P. S. Pan, R. C. Vasko, S. A. Lapera, V. A. Johnson, R. P. Sellers, C. C. Lin, C. M. 
Pan, M. R. Davis, V. C. Ardi, S. R. McAlpine. Bioorg. Med. Chem. 2009, 17(16), 5806-
5825. 
 [45]  R. C. Vasko, R. A. Rodriguez, C. N. Cunningham, V. C. Ardi, D. A. Agard, S. R. 
McAlpine. ACS Med. Chem. Lett. 2010, 1(1), 4-8. 
 [46]  R. P. Sellers, L. D. Alexander, V. A. Johnson, C. C. Lin, J. Savage, R. Corral, J. Moss, 
T. S. Slugocki, E. K. Singh, M. R. Davis, S. Ravula, J. E. Spicer, J. L. Oelrich, A. 
Thornquist, C. M. Pan, S. R. McAlpine. Bioorg. Med. Chem. 2010, 18(18), 6822-6856. 
 [47]  L. D. Alexander, R. P. Sellers, M. R. Davis, V. C. Ardi, V. A. Johnson, R. C. Vasko, 
S. R. McAlpine. J. Med. Chem. 2009, 52(24), 7927-7930. 
 [48]  C. L. Carroll, J. V. Johnston, A. Kekec, J. D. Brown, E. Parry, J. Cajica, I. Medina, K. 
M. Cook, R. Corral, P. S. Pan, S. R. McAlpine. Org. Lett. 2005, 7(16), 3481-3484. 
 [49]  M. R. Davis, E. K. Singh, H. Wahyudi, L. D. Alexander, J. B. Kunicki, L. A. 
Nazarova, K. A. Fairweather, A. M. Giltrap, K. A. Jolliffe, S. R. McAlpine. Tetrahedron 
2012, 68(4), 1029-1051. 
 [50]  J. B. Kunicki, M. N. Petersen, L. D. Alexander, V. C. Ardi, J. R. McConnell, S. R. 
McAlpine. Bioorg. Med. Chem. Lett. 2011, 21(16), 4716-4719. 
 [51]  P. S. Pan, K. L. McGuire, S. R. McAlpine. Bioorg. Med. Chem. Lett. 2007, 17(18), 
5072-5077. 
 [52]  R. A. Rodriguez, P. S. Pan, C. M. Pan, S. Ravula, S. Lapera, E. K. Singh, T. J. Styers, 
J. D. Brown, J. Cajica, E. Parry, K. Otrubova, S. R. McAlpine. J. Org. Chem. 2007, 72(6), 
1980-2002. 
 [53]  T. J. Styers, A. Kekec, R. Rodriguez, J. D. Brown, J. Cajica, P. S. Pan, E. Parry, C. L. 
Carroll, I. Medina, R. Corral, S. Lapera, K. Otrubova, C. M. Pan, K. L. McGuire, S. R. 
McAlpine. Bioorg. Med. Chem. 2006, 14(16), 5625-5631. 
 [54]  G. N. Belofsky, P. R. Jensen, W. Fenical. Tetrahedron Lett. 1999, 40(15), 2913-2916. 
 [55]  R. H. Baltz. Nat. Biotechnol. 2006, 24(12), 1533-1540. 
 [56]  L. Van Melderen. I. J. Med. Microbiol. 2002, 291(6-7), 537-544. 
 
 
 
 
 
 
B. Publications                                                             
70 
 
 
Supporting information 
 
Table of content 
 
Table S1   NMR spectral data for luminmide C (3) in DMSO-d6 
 
Table S2 Point mutation by Red/ET recombination in combination with ccdB 
counterselection 
 
Figure S1 Direct and inverse feeding experiments of luminmide C (3) 
 
Figure S2 Direct and inverse feeding experiments of luminmide D (4) 
 
Figure S3 Direct and inverse feeding experiments of luminmide E (5) 
 
Figure S4 Direct and inverse feeding experiments of luminmide F (6) 
 
Figure S5 Direct and inverse feeding experiments of luminmide G (7) 
 
Figure S6 Comparative HPLC/MS chromatograms of WT and mutated Plu3263 
expressed in E. coli GB05-MtaA. 
 
 
 
 
 
 
 
 
 
 
 
B. Publications 
71 
 
Table S1 NMR spectral data for luminmide C (3) in DMSO-d6 
 
unit position δC, type 
a
 δH (J in Hz)
 b
 
Ile 1 172.02, qC  
 2 54.9, CH 4.32 (m) 
 3 37.1,CH2 1.60 (m) 
 4 25.8, CH 1.06 (m), 1.265 (m) 
 5 11.3,CH3 0.85 (m) 
 6 14.0, CH3 0.76 (d, 6.82) 
 NH  7.50 (d, 9.31) 
Leu-1 1 171.87, qC  
 2 52.1, CH 4.03 (m) 
 3 38.6, CH2 1.12 (m), 1.33 (m) 
 4 23.6, CH 0.83 (m) 
 5 21.6, CH3 0.712 (d, 6.51) 
 6 22.6, CH3 0.623 (d, 6.64) 
 NH  8.56 (d, 6.33) 
Phe-2 1 170.57, qC  
 2 55.4, CH 4.23 (m) 
 3 36.5, CH2 2.75 (m), 3.12 (m) 
 4 138.1, qC  
 5 128.4, CH 7.25 (m) 
 6 125.9, CH 7.19 (m) 
 7 123.4, CH 7.18 (m) 
 NH  8.86 (d, 8.03) 
Leu-2 1 171.56,qC  
 2 51.8, CH 4.30 (m) 
 3 40.0, CH2 1.40 (m), 1.67 (m) 
 4 24.8, CH 1.39 (m) 
 5 23.0, CH3 0.853 (m) 
 6 22.1, CH3 0.89 (m) 
 NH  7.39 (d, 6.67) 
Leu-3 1 170.45, qC  
 2 49.8, CH 4.34 (m) 
 3 36.2, CH2 1.43 (m), 1.52 (m) 
 4 24.0, CH 1.56 (m) 
 5 22.6, CH3 0.87 (m) 
 6 21.3, CH3 0.787 (d, 6.41) 
  NH  8.88 (d, 7.82) 
a
Recorded at 175 MHz; referenced to residual DMSO-d6 at δ 39.51 ppm. 
 
b
Recorded at 700 MHz; referenced to residual DMSO-d6 at δ 2.50 ppm. 
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Table S2. Point mutation in NRPS gene by Red/ET recombination in combination with ccdB counter 
selection 
position plu3263 plu3263* 
RE digestion 
correct 
Sequencing 
correct 
C278M TGT (Cys) ATG (Met) 3/24 3/3 
C278T TGT (Cys) ACC(Thr) 3/18 3/3 
I299F ATA(Ile) TTC(Phe) 6/22 6/6 
A301G GCA(Ala) GGT(Gly) 6/24 2/6 
I299F/A301G ATA(Ile)/GCA(Ala) TTC(Phe)/GGT(Gly) 5/28 3/5 
C278M/A301G TGT (Cys)/GCA(Ala) ATG (Met)/GGT(Gly) 2/16 2/2 
S2742A (PCP3) TCG(Ser) GCG(Ala) 15/24 6/6 
   30/156  19.2% 25/31    80.6% 
    Total.15.5% 
RE means restriction endonuclease 
 
 
 
 
Figure S1. Direct and inverse feeding experiment of luminmide C (3). A) Direct feeding. B) Inverse 
feeding. 
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Figure S2. Direct and inverse feeding experiment of luminmide D (4). A) Direct feeding. B) Inverse 
feeding 
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Figure S3. Direct and inverse feeding experiment of luminmide E (5). A) Direct feeding. B) Inverse 
feeding 
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Figure S4. Direct and inverse feeding experiment of luminmide F (6). A) Direct feeding. B) Inverse 
feeding 
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Figure S5. Direct and inverse feeding experiment of luminmide G (7). A) Direct feeding. B) Inverse 
feeding. 
 
 
Figure S6. Comparative HPLC/MS chromatograms of WT and mutated Plu3263 expressed in E. coli 
GB05-MtaA. Luminmide A, EIC, m/z 586  [M+H]
+
; Luminmide B, EIC, m/z 552  [M+H]
+
; 
Luminmide C, EIC, m/z 600  [M+H]
+
; Luminmide D, EIC, m/z 566  [M+H]
+
. 
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C. Final discussion 
1 RecE/RecT mediated linear-linear homologous recombination facilitates 
direct cloning for bioprospecting 
The routine sequencing of bacterial genomes and recent progress in bioinformatics (e.g., 
antiSMASH which can quickly identify biosynthetic loci and predict types of compounds),
38
 
allow for the rapid detection of large numbers of cryptic biosynthetic gene clusters that 
potentially govern the biosynthesis of novel biologically active compounds. However, the 
low expression level of biosynthetic genes in laboratory conditions results in low amount or 
nonproduction of natural products which often precludes them from being mined during 
conventional screening.
45
 Even if a compound is detected, low yield may restrain following 
purification, structure elucidation and biological activity test. Many genomic-based 
approaches that are currently employed for investigating silent gene clusters rely on 
provoking their expression in the native host through the optimizations of culture condition or 
engineering of regulatory genes. An alternative and potentially better approach to excavate 
potential novel products is the heterologous expression of silent clusters in a well-
characterized host, e.g., E. coli and several Streptomyces species, using sophisticated DNA 
manipulation techniques.
79
 However, some challenges, such as difficulties in cloning and 
engineering large gene clusters and lack of suitable heterologous hosts, hinder the application 
of this strategy. 
The efficient cloning of cryptic gene clusters, which usually span 20-100 kb of DNA, 
remains a restriction for heterologous cluster expression besides the obvious problem of 
defining suitable/optimized host. The construction of gene libraries, screening them for target 
clusters, and stitching clusters together from regions spanning more than one clone have 
become prevalent. In addition, synthetic biology methods for the assembly of DNA (gene, 
biosynthetic pathway and even entire chromosome) from small synthetic DNA fragments 
have been developed. Although it allows codon usage and regulatory elements to be host-
optimized for optimal performance, it remains rather expensive and it has the potential to 
introduce annoying random mutation.  
The direct cloning method mediated by full length RecE and RecT presented in this thesis 
relies on the functional distinction and replication-independent recombination - LLHR. The 
LLHR refers to the homologous recombination between a linear E. coli vector flanked by two 
homologous arms which defines the limits of the target insert, and the linear target DNA 
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segment which is present in a digested genomic DNA mixture. The full length RecE/RecT 
which catalyzes homologous recombination between two linear DNA molecules with more 
than 20-folder greater efficiency compared to both truncated versions of RecE/RecT and 
Redα/Redβ pairs which are more superior for LCHR. We immediately implemented this new 
technique for the direct cloning of bacterial secondary metabolite biosynthetic pathways from 
digested genomic DNA of P. luminescens. This lead to discovery of two groups of 
compounds, luminmycins and luminmides, by heterologous expression of the pathways in E. 
coli strains Nissle 1917, and GB05-MtaA, respectively. In this case, we screened and 
engineered E. coli strain GB2005 and GB2006 to minimize the endogenous recombination 
occurring between the highly repetitive DNA regions of PKS and NRPS clusters. This issue 
enables these large heterologous DNA to be stable in E. coli and avails for the next step 
engineering and expression. Furthermore, in our cloning strategy, a tetracycline inducible 
promoter (PtetO) was included in the linear cloning vector. After LLHR, the native promoter 
and ribosome binding site (RBS) at the upstream of first open reading frame of an operon in 
the target cluster were changed to an inducible promoter, sometime the uncommon/alternate 
start codons like GTG and TTG were altered to ATG at the same time. This exchange was 
performed based on two considerations: 1), the native promoter or regulatory genes may not 
function in the unrelated or phylogenetically distant host, thus the exchange of the promoter 
would enable expression in the heterologous host. 2), in our experience, foreign PKS/NRPS 
clusters are often toxic to the heterologous host when constitutively expressed. Consequently 
establishing the gene cluster under the control of an inducible promoter is the best choice for 
both plasmid maintenance and gene expression.  
Although NRPS gene clusters up to 52 kb in size have been directly cloned from purified 
P. luminescens genomic DNA (5.7 Mb) with high efficiency (6/21) using a two-step strategy 
combining both LLHR and LCHR,
211
 it is still a challenge to clone large gene cluster (>60kb) 
from even bigger chromosomes. Because the cloning efficiency decreases with an increasing 
size of the target gene cluster, we generally used a more complex strategy combined with 
LLHR to clone them. For example, the ~81 kb rhizoxin biosynthetic gene cluster from 
Pseudomonas fluorescens Pf-5 was separately (approximately 48 kb for upstream part, 36 kb 
for downstream part) cloned into p15A vectors by LLHR from digested genomic DNA. In the 
stitching step, the upstream part was initially subcloned into a BAC vector by Red/ET 
recombineering, then the downstream part was digested and ligated into the BAC construct 
containing upstream part to reconstitute the complete rhizoxin biosynthetic pathways(~ 91 
kb).
212
 The direct cloning of various PKS/NRPS gene clusters by LLHR from the genomes of 
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Gram-negative bacteria (E. coli Nissle, Photorhabdus luminescens, Xenorhabdus sp., 
Pseudomonas syringae and P. fluorescens, Burkholderia DSM7029 and Burkholderia glumae, 
myxobacteria Myxococcus xanthus and Sorangium cellulosum) and Gram-positive bacteria 
Streptomyces coelicolor, Paenibacillus larvae and Bacillus thuringiensis have in the 
meantime been accomplished by our group and our partners (unpublished data), which 
demonstrates the powerful capability and wide adaptability of direct cloning for potential 
bioprospecting. 
 
Figure C-1. Strategy of Red/ET recombineering mediated genomic-based bioprospecting of microbes 
for new bioactive natural product. 
Using Red/ET recombineering, including LLHR by RecET and LCHR by Redαβ, cloning 
and mutagenesis of secondary metabolite pathways can be rapidly performed in E. coli. 
Coupled with heterologous gene cluster expression in a versatile host, a genomic-based 
bioprospecting of microbes for new bioactive natural products can be proposed (Figure C-1). 
The genome of microbial isolates can be sequenced rapidly and then analyzed by 
bioinformatics software such as antiSMASH to define the gene clusters of interest. Genomic 
DNA can be digested using suitable enzymes to release the chosen gene clusters onto single 
genomic DNA 
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DNA fragments and they can be direct cloned into an E. coli expression vector by LLHR for 
expression in an appropriate host to discover their products. The resulting constructs can also 
be modified by LCHR to exchange internal promoter(s), inactivation of repressors, or 
overexpression of positive regulators, to increase titers of products for bioactivity assay. The 
biosynthetic gene cluster encoding potential lead compounds can be further manipulated (e.g. 
site-directed mutagenesis, or deletion, insertion, fusion, swapping of domains or modules, or 
pathway fusion) by LCHR and other tools (e.g., digestion and ligation) for combinatorial 
biosynthesis to generate more derivatives for lead optimization. A more important issue is the 
choice of or engineering an ideal heterologous host for a specific gene cluster, such as 
addition of precursor biosynthetic pathway (MM-CoA for biosynthetis of most polyketides) 
and PPTase (Sfp, MtaA) into E. coli, or deletion of completing biosynthetic pathways. A 
couple of cryptic secondary metabolites were discovered by direct cloning following by 
heterologous expression in E. coli, P. putida, and Burkholderia species. Along with the 
successful genetic engineering of luminmide, luminmycin and syringolin biosynthetic 
pathways to change metabolite profile or generate new derivatives, prove Red/ET 
recombineering is a powerful tool for cloning and engineering of cryptic bacterial secondary 
metabolite biosynthetic pathways and promotes genomic-based natural product 
bioprospecting in a post-genomics era.  
Admittedly, LLHR also has several limitations. It is contingent on the presence of unique 
restriction enzyme sites both upstream and downstream of the interested gene cluster to 
release it into single DNA segment, as the distance between the location of the restriction 
sites and chosen homology arm greatly affects the recombination efficiency. Otherwise, more 
rounds of Red/ET recombineering would be required to engineer the promoter, add necessary 
genes, or delete redundant sequences. Another problem which may be caused by LLHR is the 
mutations at 5′ ends of two cloned gene clusters, preventing functional expression. These 
results suggested they are toxic to E. coli cloning host even under the control of inducible 
promoter but without induction. More tightly regulated promoters are required in the future. 
At least, LLHR simplify the process for cloning of large gene clusters. 
However, the successful expression of an unknown gene cluster is usually unpredictable 
owing to the differences between native and heterologous host, which may not produce all 
necessary precursors or low-production escaped from detection due to the inappropriate 
choice of heterologous host. It is safe to select the heterologous host which is related or close 
to native producer, increasing the possibility for successful expression. In our case, we cloned 
10 gene clusters from P. luminescens, and seven were tried to express in the phylogenetically 
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close E. coli strain, but only two were successfully expressed to identify their products. In 
addition, successful expression may require several attempts with different heterologous 
hosts, but we only used the poor heterologous host E. coli for expression of unknown natural 
products. The further attempts of the other heterologous host would lead to identification of 
more compounds. In the other hand, the problem of pathways aspect includes the possibility 
of an internal promoter(s) or regulator(s) which may make the gene cluster ‘silent’ in a 
heterologous host. Guided by increasing understanding of biosynthesis and regulation of 
secondary metabolites, it can be readily addressed by Red/ET recombineering mediated gene 
targeting once a clone has been obtained. Hence, we have to search more ‘universe’ 
heterologous hosts and rationally manipulate cloned biosynthetic pathways in future work for 
robust heterologous expression and application of this strategy. To sum up, the development 
of Red/ET recombineering followed by suitable heterologous expression would promote 
natural product discovery and optimization. 
2 A site-directed mutagenesis approach for NRPS: ccdB counterselection 
recombineering 
Site-directed mutagenesis, also called site-specific mutagenesis or oligonucleotide-
directed mutagenesis, is a molecular biology technique often used in bioengineering in which 
a mutation is created at a defined site in a DNA molecule. There are a number of methods for 
achieving this, e.g., overlapping PCR. Ideally, site-directed mutations should be seamless so 
that the final product does not include any unnecessary sequence that was acquired during 
mutagenesis, and it would best be performed in vivo so that unexpected mutations at the non-
target sequence, which may be introduced by PCR methods, can ultimately be avoided, 
especially for the large constructs. These potential mutations are particularly important for 
mutagenesis within protein-coding regions of bacterial secondary metabolite biosynthetic 
megasynthetases where extraneous subtle changes would cause significant alteration of final 
production or even completely abolish it. The in vivo seamless mutagenesis can be efficiently 
achieved using counterselection recombineering strategy which utilizes counterselectable 
marker and Red/ET recombining. We report a method for performring site-directed 
mutagenesis, independent of traditional medium supplementation that utilizes ccdB as the 
counterselective marker.  
We employed the ccdB as a counterselectable marker combined with Red/ET 
recombineering to specifically alter a few bases without introducing  any unwanted sequence 
in the NRPS gene plu3263 presented in a multi-copy plasmid pBR322 with a rational 
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efficiency (~15%). ccdB encodes a lethal protein that targets DNA gyrase. It can be 
propagated in E. coli strain DB3.1 which harbors a specific mutation in the gyrase rendering 
it resistant. In the first step of recombineering, the target sequences is replaced with a ccdB-
Cm cassette including chloramphenicol resistant gene and counterselectable marker ccdB 
which is performed in DB3.1 strain containing redγβα expression plasmid. In the second step, 
the oligonucleotide-mediated recombineering was also performed in the DB3.1 strain 
containing Redγβα to form the plasmid mixture of repaired and unrepaired constructs in one 
cell. Because pBR322-derived plasmid is multi-copy, it is possible that only several copies can 
be repaired by single-stranded oligonucleotide but most copies will still contain ccdB. In order 
to select the repaired plasmid efficiently, the plasmids were extracted immediately from 
DB3.1 and retransformed into the ccdB-sensitive E. coli strain GB2005, thus only the mutant 
without ccdB can grow on the plate. However, not all the viable clones were the correct 
mutants; where possible intramolecular recombinants were generated removing the ccdB to 
allow the survival of E. coli strain GB2005, which was the most probable reason for the 
observed background of incorrect recombinants. Using this counterselection pattern through 
host change, even one copy of repaired plasmid can be selected and thus is a robust method 
for introducing point mutations into a multi-copy plasmid. One limitation of this 
counterselection method is that success is extremely dependent on the transformation 
efficiency, especially for large plasmid mutagenesis, but this is addressed by using the strain 
with the highest efficiency for the transformation of large plasmids - GB2005 (unpublished 
data). As a result of performing the site-directed mutagenesis of plu3263, only 15% of the 
recombinants were correct. While this fraction is low, the method is still relatively efficient, 
considering the iterative features of modules/domains in large NRPS biosynthetic genes and the 
mutation position in the middle of repetitive NRPS gene that would frequently lead to 
intramolecular recombination. The incorrect mutants in this investigation are the intramolecular 
recombinants between the regions upstream (module 1 and 2) and downstream (module 4 and 5) 
of module 3 (where the target sequence is located) as supported by restriction digestion 
examination. Several measures have been applied in the rpsL counterselection-based 
recombineering method to reduce these unwanted events, such as expressing Redβ alone at 
crucial step or using phosphothioated oligonucleotides, to improve the efficiency of site-directed 
mutagenesis in BAC.
206
 These measures may also be implemented into ccdB counterselection 
recombineering to enhance the likelihood of obtaining the correct point mutations in multi-copy 
plasmid. 
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The efficient ccdB counterselction recombineering enriches the genetic engineer’s tool kit 
and provides a powerful alternative for seamless modification of PKS and NRPS, which include 
not only site-directed mutagenesis using single stranded DNA as a substrate, but also 
domain/module swapping, and deletion using double stranded DNA (usually PCR product).  
3 Examples: luminmides, luminmycins, syringolins 
We used those two developed techniques,  direct cloning and site-directed mutagenesis for 
cloning and engineering of cryptic luminmide and luminmycin biosynthetic pathways from P. 
luminescens, and for the known syringolin gene cluster from P. syringae. 
3.1 Luminmide 
The gene plu3263 was directly cloned from genomic DNA of P. luminescens by LLHR 
and heterologously expressed in E. coli GB05-MtaA to uncover its previously secret seven 
products, Luminmides A-G. The diversity of luminmides stems from the NRPS substrate 
promiscuity. From the structural, genetic and bioinformatics analysis, the initiation module 
(A1-T) can select two amino acids Val or Ile, and the third module (E/C-A3-T) can activate 
five amino acids Phe, Leu, Val, Tyr or Met to give a diversified product scaffold. The NRPS 
substrate promiscuity is not uncommon and also present in other pathways such as 
tyrocidine
213
 and xenematide.
214
  
To further exploit this chemical diversity, we enforced ccdB counterselection 
recombineering to change several active residues followed by robust heterologous expression 
to compare the metabolic profiles of WT and mutated Plu3263. Six mutants were created and 
indeed great variation was found in the abundance of luminmides A-D due to the alteration of 
substrate specificity of A3 domain. In C278T mutant, the production of luminmide A is still 
higher than other analogs. But in all the remaining mutants, the WT minor product luminmide 
B became the dominant product, and the yield of luminmide A decreased to diffident extents 
and was completely abolished in the double mutant C278M/A301G. Thus our results from 
altering the specificity of A3 domain by site-directed mutagenesis of the ‘specificity-
conferring code’ are highly encouraging as basically the domain could be altered in a way 
that enabled almost complete reprogramming. Gly301 mutaion is more efficient than Ala301, 
and Met278 is more efficient than Cys278, for activating of Leu in A3 domain, while the 
Thr278 is less efficient than native Cys278 for selection and incorporation of Phe into 
luminmides. The latter conflicts with the fact that Thr278 presents in most of Phe-activating 
A domains but Cys278 is rare. In addition, the increase of luminmide G in the mutant C278M 
is consistent with our anticipation that Met in position 278 is also beneficial for recognition 
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of Val. The production of luminmide F and B are also increased in the mutant A301G, which 
implies that the ‘specificity-conferring code’ of Met-activating A domain may be similar to 
that of Leu, because a Met-activating A domain is rare in NRPS. Moreover, this site-directed 
mutagenesis is a feasible way to remove the predominant compound and/or improve yield of 
subordinate product, which can simplify purification procedure of low-level secondary 
metabolites, such as luminmide B here (Chapters 1 and 4).  
3.2 Luminmycin 
After the genome sequence of P. luminescens was published, several hidden PKS/NRPS 
biosynthetic gene clusters were found and structures of their products were predicted based 
on the NRPS rules for substrate specificity of A domains in the website NPbiogene 
(www.npbiogene.com, unavailable now).
215
 A NRPS/PKS biosynthetic pathway was 
predicted from plu1864-plu1886 genes and the corresponding putative compound was named 
luminmycin in this webpage (Figure C-2).
215
 Blast analysis showed that this gene cluster 
(plu1881-plu1877) is highly similar to the glidobactin gene cluster from Burkholderia K481-
B101 except for the absence of glbH and glbE homologs.
216
 The genes plu1864 to plu1876 
organized and transcribed in a different direction to plu1881-plu1877 and therefore it is 
unlikely that they belong to one operon. The genes plu1883-plu1885 (bkdA-bkdC) encoding 
enzymes for production of iso-fatty acids are involved in stilbene biosynthesis.
217
 The gene 
plu1882 encodes a glycoporin and is not a secondary metabolite biosynthesis-related protein. 
Thus we speculated that the plu1881-plu1877 would encode an intact biosynthetic pathway 
and may generate glidobactin-like compounds. But no glidobactin analog was detected from 
the extract of P. luminescens WT strain using HPLC/MS analysis.  
The plu1881-plu1877 was directly cloned by LLHR and expressed in E. coli strain Nissle 
1917 from which glidobactin is successfully heterologous expressed. There luminmycins 
were identified by comparative metabolome analysis and luminmycin A was found to be a 
10-deoxy derivative of the previously reported glidobactin A, while luminmycins B and C 
most likely represent its acyclic biosynthetic intermediates (Figure A-12). Introduction of 
glbH into plu1881-plu1877 leads to the partial conversion from luminmycin A to glidobactin 
A which demonstrates that GlbH involves in the formation of 4-hydroxylysine. Luminmycin 
A showed slightly weaker cytotoxicity than glidobactin indicating that the C-10 hydroxy 
group is a positive factor for cytotoxicity, while acyclic luminmycin B exhibited no activity 
at concentrations as high as 100 µg/mL.
218
 The cryptic plu1881-plu1877 was elucidated by 
heterologous expression in E. coli. Thus, the Red/ET recombineering mediated activation and 
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expression of cryptic biosynthetic gene clusters in heterologous hosts is shown to be a 
powerful tool for bioprospecting. 
 
Figure C-2. The proposed luminmycin biosynthetic pathway from plu1864 to plu1886 in NPbiogene 
website.  
The biosynthetic pathway for luminmycin was proposed based on comparative 
bioinformatics, genetic and structural analysis with glidobactin. The tripeptide part of 
luminmycin is formed by the NRPS/PKS megasynthetase, Plu1878 and Plu1880. Based on 
the signature sequence of the NRPS A domain, Plu1878, a homologue of GlbC, is predicted 
to activate Thr which is the N-terminal amino acid and it is N-acylated with 2(E), 4(E) 
dodecadienoic acid (Dda). This module contains a condensation domain prior to the first 
amino acid activation domain and this starter C domain would utilize fatty acyl-CoA to 
acylate the Thr amino group and generate an intermediate for subsequent chain elongation.
219
 
The Plu1880, a homologue of GlbF, is a NRPS/PKS hybrid protein including two NRPS 
modules and one PKS module. Its first and second NRPS modules are predicted to activate 
Lys which differs from glidobactin, 4-hydroxylysine, and Ala which is the same as 
glidobactin, respectively. If the hydrolysis happens in the second thiolation domain of 
Plu1880 it would result in the release of luminmycin C where one PKS extender unit is 
lacking. The PKS module would load malonyl-CoA and condense it into peptidyl chain and 
then undergo β-carbon reduction by KR and DH domains. Luminmycin B may be the 
C. Discussions 
87 
 
hydrolysis product of β-hydroxyacyl-S-T prior to dehydration in β-carbon processing. Then, 
the last cyclization should be achieved by the TE domain to generate luminmycin A.  
The gene plu1881 and glbB encodes a hypothetical protein containing a conserved domain 
BsmA which is a biofilm formation and stress response factor.
220
 Plu1881 also shows weak 
similarity (Identities 26%, Positives 46%) to L-isoleucine-4-hydroxylase from Bacillus 
thuringiensis.
221
 Because glbB is essential for glidobactin biosynthesis,
216
 we reasoned 
Plu1881 may also be involved in the hydroxylation of lysine residue together with GlbH 
which is a dioxygenase-related protein. The fact that glbH mutant of Burkholderia K481-
B101 can still produce trace glidobactin A shows one or more another gene products (e.g. 
Plu1881/GlbB) also responsible for the hydroxylation of lysine because the lack of the 
corresponding proteins may have impaired the function for hydroxylation. This could be 
testified by in vitro biochemical characterization, or deletion of glbB which caused the 
completely abolishment of glidobactin A but not loss of luminmycin A. Another homolog 
absent from luminmycin gene cluster is glbE encoding an MbtH-like protein which activates 
the A domains of NRPS GlbF,
219,222
 but is not essential for biosynthesis of luminmycin. 
Addition of glbF into plu1881-plu1877 does not improve the production of luminmycin. The 
plu1877 and glbG encode ketosteroid isomerase-related proteins which may be involved in 
the biosynthesis of 2(E), 4(E) dodecadienoyl-CoA from unsaturated fatty acids.
223
 The 
putative exporter Plu1879, a homologue of glbD and sylE, the exporters of glidobactin
216
 and 
syringolin,
224
 respectively, is hypothesized to also mediate luminmycin A export.  
Luminmycins can also be one member of syrbactin beside syringolin and glidobactin,
225
 
which stands for a new class of potent proteasome inhibitors acting by the covalent 
attachment between the α,β-unsaturated carbonyl group of the 12-membered macrocylic core 
and the active site Thr1 of the 20S eukaryotic proteasome through a Michael-type 1,4-
addition.
226,227
 The high cytotoxicity of luminmycin A and the inactivity of open-ring 
luminmycin B are correlated well with the mechanism of proteasome inhibition.  
3.3 Syringolin 
We used LLHR to directly clone the partial biosynthetic pathway (sylCDE) from genomic 
DNA and then successfully expressed in a heterologous host E. coli GB05-MtaA, which 
resulted in the identification of two new members of the syringolins, syringolins G and H 
(Figure A-12). Both of compounds are Lys-saturated products of syrongolins F and C as a 
result of seizure of SylB.
228
 
The gene sylB encodes a desaturase that would act specifically on Lys to form a non-
natural derivative 3,4-dehydrolysine, the substrate for the first NRPS module of SylD. 
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Presumably due to toxicity of 3,4-dehydrolysine to E. coli, the heterologous overexpression 
of recombinant SylB was unsuccessful, hence the function of SylB was unable to be 
characterized in vitro.
229
 But the desaturation occurred prior to activation and elongation by 
the SylD assembly line which was proven by the A domain preference for the activation of 
3,4-dehydrolysine to lysine. Thus, heterologous expression of the remainder of the 
biosynthetic pathway combined with in vivo identification of Lys-saturated syringolins is an 
alternative way to identify the function of SylB in vivo. In the deleted sylB mutants, all the 
Lys-desaturated syringolins, syringolins A, C, D, and F, were completely abolished but Lys-
saturated syringolins B and E, as well as newly discovered G and H were still present. This 
fact confirms that SylB catalyzes the desaturation of Lys to form 3,4-dehydrolysine in vivo.   
The whole syringolin gene cluster was also reconstructed by addition of sylB and promoter 
exchange of a synthetic bidirectional promoter in place of the native promoter region to drive 
sylB and sylC. The genes sylAB were inserted into sylCDE to complete the syringolin gene 
cluster in which has an identical genetic organization, promoter and regulatory gene to the 
native producer. This construct also produced all eight syringolins when expressed in E. coli 
GB05-MtaA, but the production of Lys-desaturated syringolins was lower than that of Lys-
saturated syringolins which may be partly due to the native promoter and regulatory gene 
being less active in E. coli. So we deleted the putative regulatory gene sylA and introduced a 
synthetic bidirectional promoter between sylB and sylC because the two genes are arranged in 
different transcription direction. The results showed an increase in the production of Lys-
desaturated syringolins due to the stronger function of a synthetic promoter than native 
promoter in E. coli. Certainly, changing the native promoter to a more potent promoter can 
influence bacterial secondary metabolite production yields in both heterologous and native 
host. The Tn5-derived npt promotor or T7A1 promoter were inserted into the upstream of 
NRPS/PKS genes of thuggacin or myxoprincomide biosynthetic pathways in their native 
producers, Chondromyces crocatus and M. xanthus, respectively, which greatly improved 
their yields.
59, 230
 Such an approach may ultimately prove fruitful for up-regulating 
biosynthesis from some of the many natural product gene clusters in native host, for which no 
product is currently known. Besides, the heterologous expression of biosynthetic gene 
clusters in an unrelated host generally requires the native promoter to be changed. For 
example, replacement of the native promoter of myxochromide S biosynthetic pathway from 
S. aurantiaca to toluic acid inducible Pm promoter led to improved production in P. puptida.
87
 
The heterologous expressions of biosynthetic pathways from a Paenibacillus species or a 
cyanobacterium were also achieved in E. coli GB05-MtaA by exchanging the native 
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promoter with L-arabinose inducible PBAD or tetracycline inducible promoter (unpublished 
results). The promoter exchange together with heterologous expression in E. coli also 
awakens the silent luminmycin biosynthetic pathway in P. luminescens. Promoter 
engineering is an important factor to be considered for effective heterologous expression of 
bacterial secondary metabolites biosynthetic pathways. 
4 Summary 
Bacterial genome-sequencing projects have revealed that the majority of natural product 
biosynthetic pathways cannot currently be correlated to compounds and thus offers the 
opportunity for the discovery of novel bioactivies. Cloning, engineering and expression of a 
biosynthetic pathway of unknown function in a well-characterized heterologous host is an 
effective approach to discover and optimize its products, especially if the genes are derived 
from slow growing bacteria or such one for which genetics are only poorly or not at all 
established. The efforts towards genome sequencing, stitching of large secondary metabolite 
biosynthetic pathways by Red/ET recombineering, and efficient transfer of large gene 
clusters into heterologous hosts by transposition established a pipeline for the heterologous 
expression of large natural product biosynthetic pathways. In the current study, LLHR 
mediated direct cloning together with well-established genetic engineering of large gene 
clusters from genomic DNA, followed by robust heterologous expression promoted 
identification of some of their products and generation of new derivatives. The Red/ET 
recombineering mediated direct cloning and genetic engineering is expected to play an 
important role in facilitating genomic-based bioprospecting of microbes for new bioactive 
natural products (leads) in the future. Based on this technology, now gene cloning is not 
limiting genome mining anymore. Mostly, choice of heterologous host and biosynthetic 
engineering in the respective species now represents the most important limitation of 
heterologous expression. These issues require to be addressed in the future work. 
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E. Appendix 
Author’s efforts in publications presented in this work 
Chapter 1: The author performed the construction of a heterologous host and plasmids for 
expression, annotation and bioinformatic analysis of cloned biosynthetic genes, heterologous 
expression of unknown biosynthetic gene cluster including fermentation, extraction, and 
comparative LC/MS analysis of extracts, isolation and structural elucidation of luminmides A 
and B by using HRMS, 2D-NMR and advanced Marfey’s method, and structural prediction 
of luminmycin A by comparative MS/MS fragmentation experiments. 
Chapter 2: The author generated the constructs for higher expression, isolated the pure 
luminmycins A-C and glidobactin A, determined the structures by using HRMS, 2D-NMR 
and advanced Marfey’s method. 
Chapter 3: The author designed and performed the single base pair substitution in plu3263 in 
pBR322, fermentation, extraction, LC/MS analysis of mutants.  
Chapter 4: The author designed and generated all the mutated plasmids, and analyzed the 
metabolic profiles of luminmides. Further the author purified luminmide C and identified its 
structure by NMR. The structures of luminmides D-G were also proposed by the author based 
on the feeding experiments and MS/MS fragmentation experiments.  
Chapter 5: The author constructed the expression plasmids and heterologous host for 
syringolin biosynthetic gene cluster, performed the fermentation, extraction, and LC/MS 
analysis of mutants, and analyzed the MS/MS fragmentation data for structural elucidation of 
new syringolins.  
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